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ABSTRACT
Discovery of a Novel Regulatory Mechanism of TNK1 by 14-3-3 and Its
Ubiquitin Association Domain Provides a Potential Therapeutic
Targeting Opportunity in Cancer
Tsz Yin Chan
Department of Chemistry and Biochemistry BYU
Doctor of Philosophy
While a relatively limited number of known oncogenes underlie a large percentage of
cancers, a variety of new genes have emerged as low-frequency cancer drivers. Each of these new
oncogenes represents a frontier for targeted therapy. However, the discovery of low-frequency
targetable oncogenic drivers is challenging. This study focuses on the poorly understood Tyrosine
kinase non-receptor-1 (TNK1), which has been reported to have both oncogenic and tumor
suppressive functions. TNK1 has been identified to promote cancer cells survival and promote
chemoresistance in multiple independent studies. On the other hand, whole-body constitutive
deletion of TNK1 in mice caused an increase in spontaneous carcinomas and lymphomas. All in
all, with no known regulatory mechanism and substrates of TNK1, the precise biological role of
TNK1 is still unclear.
To understand how TNK1 is regulated, we employed a proteomic approach to identify
TNK1 interactors. We found out that TNK1 interacts with the phospho-binding protein 14-3-3 and
this interaction is mediated by a cluster of MARK-mediated phosphorylations within the prolinerich domain. 14-3-3 binding retains TNK1 in the cytosol and maintains TNK1 in an inactive state.
Release of TNK1 from 14-3-3 binding drives TNK1 to a heavy membrane fraction, where it
becomes highly active. One unique feature of TNK1 is an ubiquitin association domain (UBA) on
its C-terminus. Our data suggest that the UBA domain of TNK1 binds to poly-ubiquitin chains in
nondiscriminatory manner. Remarkably, point mutations within the UBA that disrupt ubiquitin
binding abolish TNK1 activation and oncogenic signaling, suggesting a unique UBA-centric
mechanism of tyrosine kinase regulation. Finally, we used a structure-guided approach to identify
a small molecule inhibiting TNK1 with high potency and selectivity. This compound, TP-5801,
inhibits TNK1 dependent STAT3 phosphorylation. TP-5801 also prolongs the survival of mice
injected via tail vein with TNK1-driven Ba/F3 cells and reduces tumor burden in a subcutaneous
xenograft model. In conclusion, our data reveal a mechanism of TNK1 regulation that controls its
oncogenic tyrosine kinase activity and a potential strategy for TNK1 inhibition.

Keywords: TNK1, tyrosine kinase, kinase regulation, 14-3-3, ubiquitin association domain (UBA),
STAT3, inhibitor
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1. Introduction
Tyrosine kinases act as mediators of signal transduction pathways and regulate a wide array
of critical cellular processes such as cell survival, cell division and differentiation, apoptosis, gene
expression and migration. In healthy cells, the activities of tyrosine kinases are tightly regulated
to prevent unwanted survival or growth signaling. In cancer, these mechanisms of tyrosine kinase
control are often overridden via mutation, gene amplification or rearrangement, resulting in
aggressive cancer phenotypes. Indeed, tyrosine kinases have been implicated in many forms of
cancer, including leukemia, lung cancer, breast cancer, colorectal cancer and pancreatic cancer. In
recent years, tyrosine kinases have been recognized as high priority targets for anti-cancer
treatments. Examples of clinically approved tyrosine kinase inhibitors include imatinib, dasatinib
targeting BCR-Abl and gefitinib, erlotinib targeting EGFR.
With cancer sequencing projects and computational tools, many cancer driving proteins
and mutations have been identified. However, these statistical methods often only capture the high
frequency cancer drivers. While many of these frequent cancer drivers have been identified and
are being exploited for therapeutic purposes, low frequency drivers are easily missed. Discovering
low frequency driver genes is challenging yet important, as each of these new oncogenes represent
a frontier for targeted therapy. Recent examples include NTRK fusions (e.g., 0.5-4% of colorectal
cancer), ROS1 (1-2% of Non-small-cell lung carcinoma ) and ALK (~4% of Non-small-cell lung
carcinoma) all of which have therapeutics currently in the clinic1-3.
There are two classes of tyrosine kinases: receptor tyrosine kinases (RTKs) and nonreceptor tyrosine kinases (NRTKs). While RTKs function as cell surface receptors, NRTKs are
cytosolic kinases that mediate the extracellular signals from receptors to intracellular effectors.
Among NRTKs, there are several well-known oncogenes, such as SRC, JAK and ABL. Other than

these established oncogenic NRTKs, there are also potentially oncogenic NRTKs that remain
uncharacterized as possible therapeutic targets. Our study focuses on one poorly characterized
NRTK called Tyrosine Kinase Nonreceptor-1 (TNK1).

1.1. TNK1 is a member of the ACK subfamily of NRTK
NRTKs are categorized into different subfamilies based on their sequence and structure
similarities. TNK1 is a member of the ACK subfamily of NRTKs, which includes only two human
kinases, TNK1 and ACK1 (also known as TNK2). Other members include ACK2, DACK, DRP2
and Kos1. Specifically, ACK2 is a C-terminally truncated form of ACK1 identified in bovine
brain. DACK and DRP2 are the Drosophila homologs of ACK1 with difference in domain
structure. Kos1 is the murine homolog of TNK1.

Figure 1-1 Domain structure of ACK1 and TNK1.

Domain structure of the ACK family kinases
TNK1 and ACK1 have a unique domain arrangement, highlighted by an N-terminal sterile
alpha motif (SAM) domain, an SH3 domain immediately downstream of the kinase domain (both
lack an SH2 domain), and a C-terminal ubiquitin association (UBA) domain (described in more
detail below). In fact, TNK1 and ACK1 are the only two NRTKs with the SH3 domain C-terminal
to the kinase domain. With such unique domain arrangement, the regulation of TNK1 and ACK1
are likely different from other NRTKs.
-2-

Domain

Function

SAM

Dimerization; membrane association4

SH3

Involved in autoinhibition5, 6

Cdc42/Rac-interacting domain

Binding to Cdc427, 8

Clathrin-binding domain

Clathrin-mediated endocytosis 9, 10

Mig6 homology domain

Involved in autoinhibition 5

Table 1-1 Domains on ACK1 and their functions.
ACK1 is the more studied member of the ACK family and it possesses a large stretch of
regulatory domains between its SH3 domain and UBA domain, including a Cdc42/Rac-interacting
(CRIB) domain, a clathrin-binding domain and a Mig6 homology domain (MHD) (Figure 1-1).
Intramolecular interactions between different domains of ACK1 contribute to its regulation. First,
the SH3 domain of ACK1 appears to bind a proline-rich sequence at the C-terminal of MHD5.
Such interaction is believed to position the MHD, allowing the inhibitory interaction with the
kinase domain. Notably, activating mutations within the kinase domain (E346K) and SH3 domain
(M409I) were reported in ovarian and stomach cancer respectively11. These mutations promote
ACK1 activation by destabilizing the intramolecular interactions and thus release ACK1 from the
autoinhibitory state. On the other hand, the role of the CRIB domain in regulating ACK1 activation
is uncertain due to inconsistent results from independent studies7, 8.
In contrast to ACK1, TNK1 does not possess these regulatory domains, which suggests
regulatory difference between TNK1 and ACK1(Figure 1-1). TNK1 possesses a proline-rich
domain between its SH3 domain and UBA domain, by which it interacts with phospholipase Cγ112. This suggests that TNK1 might play a role in phospholipid-mediated signaling pathway.
However, there is currently no known mechanism of TNK1 regulation nor established substrates.
-3-

In fact, TNK1 has been described to be constitutively active upon expression12, 13. Additional study
is needed to understand the regulation and the biological role of TNK1.
ACK kinases signaling and their role in cancer
ACK1 has been reported to be activated by various ligands, including EGF, PDGF,
heregulin and insulin7. This suggested that ACK1 is activated downstream of RTKs and acts as a
cytosolic signal transducer to activate effector proteins. Upon EGF stimulation, ACK1 is activated
and directly drives EGFR internalization and degradation/recycling14, 15. Being a regulator of
EGFR trafficking, ACK1 indirectly regulates EGF-mediated pro-survival signaling. ACK1 is
activated downstream of PDGFR as well. Upon PDGF stimulation, PDGFR directly
phosphorylates ACK1 at Y635 to activate ACK116. Sequential activation of ACK1 leads to AKT
activation, nuclear translocation of β-catenin and cell cycle progression16. ACK1 has also been
reported to regulate cell adhesion and cell migration. Upon binding to Cdc42, ACK1 directly
phosphorylates p130Cas to promote cytoskeletal rearrangements and cell migration17. In addition,
ACK1 has been reported to phosphorylate Histone H4 and promote androgen receptor
expression18. ACK1 has also be shown to directly bind and phosphorylate androgen receptor to
promote prostate cancer progression without androgen stimulation19. Indeed, ACK1 has been
implicated as a proto-oncogene in prostate cancer, as well as leukemia, ovarian and breast cancer18,
20-25

. Thus, ACK1 is a promising therapeutic target for cancer26.
In contrast to ACK1, our knowledge on TNK1 is very limited. TNK1 was first cloned from

umbilical cord blood hematopoietic stem/progenitor cells27. TNK1 is expressed in fetal tissues, but
in adult tissues, it was described as limited to the prostate, testis, ovaries, colon and small intestine,
with no detectable TNK1 in adult heart, brain, lung or other tissues27, 28. TNK1 high expression in
fetal tissues suggest that TNK1 has an important role in embryonic development. TNK1 expression
-4-

has also been reported in various cancer cell lines, including leukemia, prostate cancer and ovarian
carcinoma cells28.
TNK1 had been identified in genome wide screens for sensitizers to gemcitabine in
pancreatic cancer and Bortezomib in myeloma29,

30

. In addition, in a retroviral insertion

mutagenesis screen in Ba/F3 cells, TNK1 was identified as a moderately oncogenic kinase

31

.

Furthermore, a hyperactive truncated form of TNK1 was identified in a patient-derived Hodgkin
Lymphoma cell line as a result of paracentric inversion. This hyperactive form of TNK1 is the
mediator of cell growth and survival of the lymphoma cell line

32

. While these studies suggest

TNK1 to be an oncogenic NRTK, whole-body constitutive deletion of TNK1 in mice caused an
increase in spontaneous carcinomas and lymphomas, primarily detectable within the
gastrointestinal tract 33—raising the question of whether TNK1 may also act as a tumor suppressor.
Additional studies report that TNK1 regulates IFN signaling by potentiating STAT1
phosphorylation34. TNK1 is also reported as a negative regulator of NF-kB and Ras-Raf-MAPK
pathway12, 35, 36.

1.2. UBA domain
One unique feature of the ACK subfamily of NRTK is that they possess a the UBA
domain6. UBA domain is a member of the alpha-helical family of the ubiquitin binding
domains(UBDs). Other UBDs include ZnF (zinc finger), PH (pleckstrin-homology), Ubc-related
(Ubiquitin-conjugating-related), SH3 and WD40 beta-propellers37, 38. There is no general ubiquitin
binding consensus motif identified among all the UBDs. Within the alpha-helical family of UBDs,
single alpha-helix and multiple alpha-helices can also define an alpha-helical UBD, and UBA

-5-

domains belong to the latter38. UBA domains are composed of three tightly packed helixes
with a hydrophobic surface patch to mediate non-covalent interactions with mono- or polyubiquitin38, 39. UBA domains can be sorted into four classes based on their preference towards
poly-ubiquitin linkages. Class 1 UBA preferably interacts with K48-linked poly-ubiquitin, class 2
UBA with K63-linked poly-ubiquitin and class 4 UBA domains bind poly-ubiquitin chains in a
nondiscriminatory manner. On the other hand, class 3 UBA does not detectably bind ubiquitin39.
UBA domains are often found in enzymes involved in proteasomal degradation, autophagy
and DNA excision-repair pathways39, 40. Examples include the E3 ubiquitin ligase Cbl and the
autophagy receptors p62/SQSTM1 and NBR1. The presence of a UBA domain on a kinase is
unusual. Indeed, ACK kinases are the only tyrosine kinases with putative UBA domains. Among
serine/threonine kinases, members of the AMPK family are the only kinases known to possess a
UBA domain. However, these UBA domains show no appreciable affinity for ubiquitin. Instead,
they form intramolecular interaction with the kinase domain to stabilize protein structure and
regulate kinase activity41-44. For ACK kinases, the nature of their UBA domain—whether it
interacts with ubiquitin and/or plays a role in kinase regulation— is still unclear. A study has
shown that a somatic mutation in the UBA domain of ACK1 (S985N), initially identified in renal
carcinoma cells, led to increased protein stability and increased cancer cell proliferation and
migration45. However, there is no explanation for the effect of the mutation nor a clear mechanism
of the function of the ACK1 UBA domain. Notably, ACK1 has been reported to directly interact
with the autophagy receptor p62/SQSTM1 via its UBA domain and ACK1 was found to be
localized on pre-autophagosome14. However, it is unclear whether ACK1 is a merely a substrate
for degradation or plays a role in autophagy.

-6-

1.3. TNK1 interacts with the phospho-binding protein 14-3-3
Our preliminary data suggest that TNK1 interacts with the phospho-binding proteins 14-33s. The human 14-3-3 family includes seven different isoforms (β, γ, ε, η, σ, τ, and ζ). Although
each isoform is expressed by a different gene, they are structurally similar46. Each isoform is
consisted of nine α-helices that form an amphipathic groove. Within the grove, positively charged
lysine and arginine residues (K49, K120, R56 and R127) are essential for 14-3-3 to interact with
the phosphate of the binding partner46, 47. Acetylated modification of the lysine residues within or
around the binding pocket may control 14-3-3 binding. 14-3-3 proteins function as homo- or
hetero-dimers to interact with Ser/Thr-phosphorylated proteins with a general consenus sequence
RXX[pS/T]XP48. For example, 14-3-3 binds to phosphorylated Bad at S75 and S99 (human
numbering) with motif sequence of RHS[pS]YP and RSR[pS]AP respectively49. However, there
are 14-3-3 binding sites that deviate from the consenus sequence as well46, 48. For example,
transcription factor FOXO3 has a 14-3-3 binding of RAV[pS]MD50; Big mitogen-activated kinase
1 (BMK1/ERK5) has a 14-3-3 binding motif of LLK[pS]LR51. Both of these 14-3-3 binding motifs
lack an arginine or a proline in the -3 and +2 positions.
14-3-3s possess no intrinsic enzymatic activity, but rather exert their effect through direct
interaction with the phosphorylated binding partner. This effect can vary from inhibition or
activation of catalytic activity, sequestration (e.g., out of the nucleus) and even scaffolding of
protein-protein interactions46. 14-3-3s interact with a large network of phosphorylated proteins and
essentially regulate all major signal transduction pathways. Since 14-3-3 isoforms share similar
structure, the 14-3-3 isoforms overlap in their binding partners in many cases. Nevertheless, in
some cases, there are also distinctive interactors and isoform-specific functions. Many protooncogenes and tumor suppressor proteins are regulated by 14-3-3s. For example, 14-3-3σ is known
-7-

to interacts with p53 to stabilize p53 for suppressing tumor growth52. 14-3-3σ expression has also
been found to be reduced or lost in many human cancers, including breast, head and neck, liver
and prostate cancers53-56. Therefore, 14-3-3σ has been generally considered a tumor suppressor
among the 14-3-3 isoforms. (Yet, 14-3-3σ has also been shown to be overexpressed in multiple
cancers where it has been shown to promote cell survival and cancer invasiveness57, 58.) On the
other hand, 14-3-3ζ is considered as an oncogene.14-3-3ζ is known to inhibit the pro-apoptotic
protein Bad and also sequester Forkhead transcription factor in the cytoplasm, preventing the
transcription of pro-apoptotic proteins49, 50. Overexpression of 14-3-3ζ correlates with cancer
progression and chemoresistance59-62.
14-3-3s are well-known regulators of kinases. For example, the kinase BRAF is locked
into an inactive confirmation by 14-3-3 binding to pS365 and pS729 of the BRAF dimer, whereas
rearrangement of 14-3-3 onto adjacent pS729 residues, spanning the BRAF dimer, locks the kinase
into an active confirmation

63, 64

. Because 14-3-3 binding is dictated by phosphorylation, 14-3-3

interactions are inherently dynamic and responsive to changes in upstream kinase signaling. In this
way, 14-3-3 acts as a central hub to orchestrate a variety of dynamic signaling events. Our
preliminary data suggest that 14-3-3s bind to TNK1. However, at this point, the exact mechanism
of how 14-3-3 is regulating TNK1 is still unknown.

-8-

2. A MARK- and 14-3-3-mediated mechanism restrains a ubiquitin-dependent mode of
TNK1 activation that can be inhibited to suppress tumor growth in vivo
*This chapter is currently under review with minor variations from this version:
Chan, TY., Egbert, C.M., Maxson, J.E., Larsen, L.J., Kohler, K., Balasooriya, E.R., Pennington,
K.L., Tsang, TM., Frey, M., Geng, H., Müschen, M., Free, S., Mercenne, G., Banks, C.J., Valdoz,
J., Whatcott, C.J., Foulks, J.M., Siddiqui, A., Bearss, D.B., O’Hare, T., Huang, D.CS., Christensen,
K.A., Moody, J., Warner, S.L., Tyner, J.W., Andersen, J.L., A MARK- and 14-3-3-mediated
mechanism restrains a ubiquitin-dependent mode of TNK1 activation that can be inhibited to
suppress tumor growth in vivo.
2.1. Abstract
TNK1 is a poorly understood member of the ACK family of non-receptor tyrosine kinases.
In this study, we identify TNK1 as a mediator of cell survival in a subset of primary specimens
from lymphoid malignancy patients. We discover a MARK-mediated phosphorylation on TNK1
at S502 that promotes an interaction between TNK1 and 14-3-3, which sequesters TNK1 and
inhibits its kinase activity. Conversely, the release of TNK1 from 14-3-3 allows TNK1 to cluster
in membrane-associated cytosolic puncta and become active. In this active state, TNK1 potently
induces growth factor-independent proliferation of lymphoid cells in cell culture and mouse
models. One feature of TNK1 is a ubiquitin-association domain (UBA) on its C-terminus, which
sits adjacent to the 14-3-3 binding site. Here, we characterize the TNK1 UBA and find that it has
high affinity for a variety of poly-ubiquitin linkages. Remarkably, point mutations within the UBA
that disrupt ubiquitin binding, also inhibit TNK1 activation and oncogenic signaling. These data
support a mechanism in which TNK1 toggles between 14-3-3-bound (inactive) and ubiquitinbound (active) states, thereby revealing a new paradigm of UBA involvement in kinase regulation.
Finally, we use a structure-guided approach to identify a small molecule TNK1 inhibitor with high
potency and selectivity. This compound, TP-5801, shows nanomolar potency against TNK1-9-

driven cells, prolongs the survival of mice injected with these cells via tail vein, and reduces
disease burden in mice with subcutaneous xenograft tumors. Together, our data reveal a novel 143-3- and UBA-mediated mechanism of tyrosine kinase regulation and identify a lead compound
for further development of a TNK1 inhibitor.

2.2. Introduction
Non-receptor tyrosine kinases (NRTKs) comprise several subfamilies of intracellular
tyrosine-directed kinases. Although these kinases differ to varying degrees in structure, many
exploit the same pathways to regulate cancer-relevant processes, including apoptosis, proliferation
and motility. The NRTK superfamily includes established oncogenes, such as SRC, ABL, JAK
and SYK-ZAP-70, many of which have been exploited for targeted therapy65. Beyond these
established oncogenic NRTKs is a subset of NRTKs that remain poorly understood and relatively
untapped as potential therapeutic targets.
Non-receptor tyrosine kinase (also known as Thirty-eight-negative kinase-1 or TNK1) is a
poorly understood kinase in the ACK family of NRTKs. TNK1 emerged as a top hit in genome
wide screens for sensitizers to chemotherapy in pancreatic cancer and myeloma29, 30. In addition,
a retroviral insertion screen in Ba/F3 cells identified TNK1 as having moderate oncogenic
activity31. Furthermore, a truncated, constitutively active form of TNK1 was identified in a
Hodgkin lymphoma (HL) cell line, which was dependent on TNK1 for growth and survival32.
While these studies cast TNK1 as an oncogenic NRTK, whole-body constitutive deletion of TNK1
in mice caused an increase in spontaneous carcinomas and lymphomas, primarily detectable within
the gastrointestinal tract33 —raising the question of whether TNK1 may also act as a tumor

- 10 -

suppressor. However, there is currently no known mechanism of TNK1 regulation nor established
TNK1 substrates, and its biological role remains unclear.
Here, we identify TNK1 as a mediator of cell survival in primary lymphoid malignancies
and uncover a mechanism of TNK1 regulation. We discover that a MARK-mediated interaction
between 14-3-3 and TNK1 restrains TNK1 localization and activity. This mechanism also involves
an unusual interplay between the TNK1 UBA, ubiquitin binding and TNK1 kinase activity,
demonstrating a novel example of kinase modulation via direct, non-covalent interaction with
ubiquitin. Importantly, disruption of 14-3-3 binding to TNK1 dramatically enhances TNK1-driven
proliferation in a UBA-dependent manner in cell culture and mouse models. Lastly, we develop a
selective and potent small molecule inhibitor that blocks TNK1-mediated cell proliferation in vivo.
Together, our data demonstrate the first mechanism of TNK1 regulation, a new paradigm of UBAubiquitin interaction in tyrosine kinase activation, and a lead compound against TNK1.

2.3. Methods
Antibodies
The following antibodies were purchased from Cell Signaling Technology: DYKDDDDK
tag mouse mAb (8146S), HA-tag mouse (2367S), Phospho Tyrosine (pTyr 1000) Rabbit mAb
(8954S), Ubiquitin Antibody Rabbit (3933S), Ubiquitin Mouse mAb (3936S), MARK3 (9311S),
GST Mouse mAb (2624S), STAT1 (14994), Phospho-Stat3 (Tyr705) Mouse mAb (4113), Stat3
rabbit mAb (12640), Phospho-Stat5 (Tyr694) (4322), Stat5 (25656) GFP mouse mAb (2955S) and
phospho-PLCγ1 (Tyr783). Monoclonal ANTI-FLAG M2 antibody (F1804) was purchased from
Sigma-Aldrich. 14-3-3 Pan Polyclonal Antibody (510700) was purchased from Thermo Fisher
Scientific. VU-1 ubiquitin antibodies (VU101) was purchased from LifeSensors. MARK1 (21552- 11 -

1-AP) and MARK2 (15492-1-AP) antibodies were purchased from Proteintech Group. MARK4
antibody (MBS8208929) was purchased from MyBioSource.

Reagents and inhibitors
Lipofectamine RNAiMAX (13778150), Pierce Protease Inhibitor Tablets (EDTA Free)
(88266), Pierce Phosphatase Inhibitor Mini Tablets (A32957), B PER Bacterial Protein
Extraction Reagent (78248), lysozyme (89833), DNaseI (90083), SEABLOCK Blocking Buffer
(37527), Life Technologies Prolong Diamond Antifade (P36961) and Pierce High Capacity
Streptavidin Agarose (20357) were purchased from Thermo Fisher Scientific. MARK1,
MARK2, MARK3, MARK4 ON-TARGETplus siRNA (L-004259-00-0010, L-004260-00-0010,
L-003517-00-0010, L-005345-00-0010) were purchased from Dharmacon. Transporter 5 (2600850) was purchased from Polysciences and Viafect Transfection Reagent (E4981) was purchased
from Promega. Recombinant Mouse IL-3 Protein (403-ML-010) was purchased from R&D
systems. Biosensor - Anti-GST (GST) Tray (18-5096) was purchased from ForteBio. AQUApure
Linear Tetra-Ub Chains (M1-link) CF (UC-710B-025), AQUApure Tetra-Ub Chains (K6-linked)
Protein, CF (UC-15-025), AQUApure Tetra-Ub Chains (K11-linked) Protein, CF (UC-45-025),
AQUApure Tetra-Ub Chains (K29-linked) Protein, CF (UC-83-025), AQUApure Tetra-Ub
Chains (K33-linked) Protein, CF (UC-103-025), AQUApure Tetra-Ub Chains (K48-linked), CF
(UC-210B-025), AQUApure Tetra-Ub Chains (K63-linked), CF (UC-310B-025), Ubiquitin (U100H), Poly-Ubiquitin/Ub2-Ub7 WT Chains (K48-linked) (UC-230) and Poly-Ubiquitin/Ub2Ub7 WT Chains (K63-linked) (UC-330) were purchased from Boston Biochem. Biotin (B46391G), Polybrene Transfection reagent (TR-1003-G) and ANTI-FLAG M2 Affinity Gel (A2220)
were purchased from Sigma-Aldrich. Phosphoblocker Blocking Reagent (AKR-103) was
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purchased from Cell Biolabs. Luciferase Assay Systems (E1500, E4030) were purchased from
Promega. Human TNK1 ORF clone in pcDNA3.1 (OHu15330C) and Anti-DYKDDDDK G1
Affinity Resin (L00432) were purchased from GenScript.
STO-609 (acetate) (15325), KN-62 (13318), BMS 345541 (trifluoroacetate salt) (16667),
LJI308 (19924) and Niclosamide (10649) were purchased from Cayman Chemical Company.
Asciminib (S8555) was purchased from Selleck Chemicals. MRT67307 (5.06306.0001) was
purchased from EMD Millipore Corporation. KN-93, ≥98% (hplc) (K1385) was purchased from
Sigma-Aldrich. KN-93, Water-Soluble (422711) were purchased from Millipore Sigma.
Hygromycin B (10687010) and Puromucin Dihydrochloride (A1113803) were purchased from
Thermo Fisher Scientific.

Maintenance of cell lines
HEK293T, HEK293A and A549 were purchased from ATCC and cultured in DMEM
supplemented with 10% FBS. Ba/F3 and FDCP1 cells were purchased from DSMZ-German
Collection of Microorganisms and Cell Cultures and were cultured in RPMI supplemented with
10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% Pen/Strep and 1 ng/mL mIL-3. HEK-293T
Lenti-X were purchased from Takara Bio and cultured in DMEM supplemented with 10% FBS.
L540 were purchased from DSMZ-German Collection of Microorganisms and Cell Cultures and
were cultured in RPMI supplemented with 20% FBS. All cells are incubated at 37oC with 5% CO2.

Viral transduction
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The retroviral firefly luciferase reporter plasmid, pMIG-BCR-ABL, packaging and
envelope plasmids were generous gifts from Dr. Michael Deininger’s group. The retroviral
pMSCV-IRES-GFP II (pMIG II) was a gift from Dario Vignali (Addgene plasmid # 52107).
pLenti-puro was a gift from Ie-Ming Shih (Addgene plasmid # 39481). To generate retrovirus,
retroviral transfer and envelope/packaging plasmid were transfected into HEK-293T Lenti-X cells
(Takara Bio) with Transporter 5 transfection reagent (Polysciences) according to manufacturer’s
protocol. 48-72 hours post transfection, retrovirus in the media were collected and centrifuged at
500xg for 5 min to clear out cell debris. To generate lentivirus, viral transfer plasmid (pLenti-puro
or pMIG) was transfected together with the packaging (pCMV-∆8.2∆vpr) and envelop plasmid
(pVSVG) into HEK-293T Lenti-X cells with Transporter 5 transfection reagent (Polysciences)
according to manufacturer’s protocol. 48-72 hours post transfection, lentiviral supernatant was
collected and centrifuged at 500xg for 5 min to clear out cell debris.

Generation of cell lines
To generate the Ba/F3 luciferase cell line, Ba/F3 cells were spinfected with firefly luciferase
reporter retrovirus with 10 ug/mL polybrene for 2 hours at 800xg at room temperature. Transduced
cells were incubated with the retrovirus for an additional 4 hours before transferring to fresh
complete growth medium. 48 hours after spinfection, transduced cells were selected with 1 mg/mL
hygromycin for 10 days. The hygromycin-resistant Ba/F3 luciferase cell line was sorted in the
presence of propidium iodide stain to one-cell-per-well into 96 well plate with BD FACSAria
Fusion flow cytometer (BD). The sorted hygromycin-resistant Ba/F3 luciferase cell lines were
tested in a luciferase reporter assay (Promega) approximately two weeks later.
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To generate the HA-14-3-3 HEK293T cell line, HEK293T cells were stably transduced with
HA-14-3-3ζ-expressing lentivirus. 48 hours post-transduction, puromycin was added to the cells
at final concentration of 3 ug/mL for 48 hours to select the transduced cells. Stable expression of
14-3-3ζ was validated by immunoblot.
To generate the FLAG-TNK1 A549 cell line, A549 cells were stably transduced with
FLAG-TNK1-expressing lentivirus. 48-hour post-transduction, cells are sorted for GFP-positive
with BD FACSAria Fusion flow cytometer (BD). Stable expression of FLAG-TNK1 was validated
by immunoblot.

Mutagenesis and cell transfection
FLAG-TNK1 expression plasmid was purchased from GenScript. All mutagenesis was
performed using Q5 Site-Directed Mutagenesis Kit (NEB), following the manufacturer’s protocol.
Cells were plated one day before transfection to obtain 40-50% cell confluency at the day of
transfection. Transfection complex was prepared at 1:4 DNA/transporter 5 ratio in DMEM and
incubated at room temperature for 20 minutes. After DNA-transporter 5 complexes were added to
the cells, cells were returned to the incubator. Media were replaced after 6 -8 hours.

Immunoprecipitation and Immunoblot
For TNK1 or 14-3-3 immunoprecipitation, transfected, transduced or stably expressing
HEK293T or A549 cells were washed and harvested in ice-cold PBS. Cell pellets were lysed in
either co-IP lysis buffer (10mM HEPES KOH pH 7.5, 150mM KCl, 0.01% IGEPAL)
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supplemented with protease and phosphatase inhibitors and rotated at 4oC for 10 mins. Lysates
were then homogenized by passaging through a 25G needle and centrifuged at 21000xg for 10
mins to clarify. Clarified lysate were collected for immunoprecipitation and/or western blot. For
FLAG or HA pulldown, lysates were incubated with anti-DYKDDDDK G1 Affinity Resin
(GenScript) or Anti-HA−Agarose (Millipore Sigma) for 1 hour at 4oC with rotation. The resins
were washed with PBS three times. The coimmunoprecipitated proteins were eluted with SDS
sample buffer by boiling at 96oC for 5 mins. Lysate were resolved by SDS-PAGE and transferred
to nitrocellulose membrane using iBlot2 Western Blotting System. Membranes were blocked with
either 5% non-fat dry milk in PBS, intercept blocking buffer (Li-cor), or 5% phosphoblocker (Cell
Biolabs) in PBST for 1 hour at room temperature. Primary antibodies against proteins of interests
were diluted 1:500 or 1:1000 in blocking buffer and incubated with blot overnight at 4oC. Proteins
were visualized and quantified using infrared fluorescent secondary antibodies (Li-cor) and LiCor Odyssey imaging system.
Transduced Ba/F3 cells were harvested and lysed in tris-triton lysis buffer (50mM Tris
pH8.0, 150mM NaCl, 1% Triton X-100) supplemented with protease and phosphatase inhibitors
(ThermoFisher Scientific). Lysates were incubated on ice and vortexed every 2 mins for 10 mins.
Lysates were then centrifuged at 21000xg for 10 mins and the supernatants were transferred to
new tubes. Lysates were then mixed with 5X SDS sample buffer and boiled at 96oC for 5 mins.
Western blotting was performed as described above.

BioID
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MCS-BioID2-HA was a gift from Kyle Roux (Addgene plasmid # 74224). TNK1 cDNA
sequence was cloned into MCS-BioID2-HA (addgene), so that the biotin ligase BirA is C-terminal
to TNK1. TNK1-BirA-HA was transfected into HEK-293T cells as described above. 36 hours
post-transfection, 50 nM of biotin was added to cells and the cells were returned to the incubator
for 10 hours. Cells were washed with ice-cold PBS three times before harvesting and lysed with
RIPA without SDS (1 M Tris pH 7.5, 10% sodium deoxycholate, 3 M NaCl, 10% Triton X 100)
as described above. Clarified lysates were incubated with Streptavidin Agarose (Thermo Fisher
Scientific) for 1 hour at 4oC with rotation. The resins were washed 4 times with lysis buffer.
Western blot was performed as described above.

siRNA silencing
Cells were seeded at 40% confluence and washed with PBS 2 times, and then Opti-MEM
(ThermoFisher Scientific) was added to the cells. The siRNA complex was prepared by incubating
Lipofectamine RNAiMAX (ThermoFisher Scientific) and siRNA for various targets at 100 nM
final concentration for 20 minutes. The complex was then added to cells and incubated for 4 hours,
after which FBS was added. After additional 8 hours of incubation, media was changed and
transfection was performed as needed.

RNAi screening of patient samples
Detailed description of the RNAi assisted protein target identification (RAPID) can be
found elsewhere66, 67 . In short, peripheral blood, bone marrow aspirates or leukapheresis samples
were obtained from cancer patients through informed consent via a protocol approved by the
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Oregon Health & Science University Institutional Review Board. Peripheral blood mononuclear
cells (PMBCs) were isolated through a Ficoll gradient and aliquoted into a 96-well plate containing
91 arrayed siRNA pools targeting the tyrosine kinome. After electroporation of siRNAs, cells were
transferred to standard cell culture media, incubated 96 hours and assayed for viability by a
tetrazolium-based MTS assay. Positive “hits” were scored for targets that reduced cell viability by
at least two standard deviations below the mean of all siRNAs on a given sample run. RNAi
silencing was confirmed by immunoblotting and qPCR. All hits were assessed by unsupervised
hierarchical clustering for each patient sample. Data were analyzed in R.

Heavy membrane fractionation
Cells were scraped from plate and rinsed with cold PBS. Cells were pelleted and then
resuspended in TEB buffer (300 mM Trehalose, 10 nM HEPES-KOH pH7.7, 80 mM KCL, 1 mM
EDTA, 5 mM Succinate) with 0.025% digitonin. Samples were left on ice for 10 minutes, mixing
every 2 minutes. The sample were centrifuged at 13000 rpm for 4 min to pellet the heavy
membrane fraction, and the supernatant was collected as the cytosolic fraction. The pellet was then
resuspended in RIPA buffer without SDS (1 M Tris pH 7.5, 10% sodium deoxycholate, 3M NaCl,
10% Triton X 100) and incubated on ice for 10 minutes. The samples were centrifuged for 3 min
at 3000 rpm and the supernatant was collected as the heavy membrane fraction. Samples were
mixed with SDS sample buffer, boiled, and loaded onto SDS-PAGE gels and subsequently western
blotted.

Expression/purification of UBA domain and Ubiquitin pull down assay
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cDNA fragments for the human TNK1 or TAB2 UBA domains were cloned into the
pGEX-6P-1 vector with GST on the N-terminus of the UBA domain. GST-only and GST-UBA
plasmids were transformed into BL21 E. coli. IPTG was added to induce expression for 3 hours at
37oC after OD600 reached 0.5-0.7. Bacteria were then centrifuged and washed with ice-cold 0.9%
NaCl solution once. Bacterial pellets were lysed with B-PER (Thermo Fisher Scientific)
supplemented with DNase I, lysozyme, and protease Inhibitor, according to manufacturer’s
protocol. The cleared bacterial lysates were incubated with glutathione agarose resin (Goldbio) for
2 hours at 4oC with rotation. The resins were washed with washing buffer (10mM HEPES pH7.5,
300mM NaCl, 1mM DTT) three times. Immobilized GST fusion proteins were incubated with
0.5µg of recombinant ubiquitin in ubiquitin pulldown buffer (150 mM NaCl, 50 mM Tris pH 7.5,
0.1% IGEPAL, 5 mM DTT, 0.25 mg/mL BSA) for 2 hours at 4oC with rotation. Immobilized GST
fusion proteins were washed four times with ubiquitin pulldown buffer. Proteins were eluted from
the resins in SDS sample buffer with 5 mM DTT in 38oC for 20 mins. Proteins were then resolved
by SDS-PAGE as described above.

Bio-layer interferometry (BLI)
Pellets of BL21 E. Coli expressing either GST-TNK1-UBA or GST-TAB2-UBA were
lysed with B-PER bacterial protein extraction reagent supplemented with DNaseI, lysozyme, and
protease inhibitor according to the manufacture protocol. Assay buffer was 50 mM Tris, 150 mM
NaCl, pH 7.2, 0.1% NP-40, 0.25 mg/mL BSA, with 5 mM DTT supplement added fresh upon each
use. Assays were done using an Octet RED96 biolayer interferometer (ForteBio) and were
performed at 30°C and 1000 rpm shaking. First, Anti-GST biosensors (ForteBio) were loaded with
GST-TNK1-UBA lysate (8 sensors, 6 for tetra-ubiquitin binding, 2 for reference control) or GST- 19 -

TAB2-UBA lysates (4 sensors, 3 for tetra-ubiquitin binding, 1 for reference control) for 60
seconds. The loaded sensors were then equilibrated in assay buffer (360 sec) followed by an
association step with a serial dilution. For TNK1-UBA, K48 tetra ubiquitin ranged from 25 nM to
0.8 nM; K63 ranged from 20 nM to 0.6 nM, for 60 seconds followed by dissociation in assay buffer
for 300 seconds. K63 and K48 tetra-ubiquitin in TAB2-UBA assay ranged from 200 nM to 50 nM,
with association for 5 or 60 seconds, respectively, followed by a 60 second dissociation. Data was
processed and analyzed in the Octet Data Analysis 8.2 software. Processed data was fit to a 1:1
binding model to obtain kinetic and thermodynamic parameters. Residuals were examined to
assess quality of fit and no systematic deviation was observed.

IL-3 independent growth assays
FDCP1, Ba/F3 or Ba/F3 stable luciferase-expressing cells were transduced as stated
previously in cell line development. Two days after transduction, cell were sorted for the GFP
positive population with BD FACSAria Fusion flow cytometer (BD). The positive population was
seeded in 24 well plates 50,000 cells per well in media without IL3. These cells were imaged using
Essen Bioscience IncuCyte ZOOM 10X objective every 4 hours for 10 days. Rate of
transformation is determined by the time required to reach 20% cell confluency.

Phospho-tyrosine proteomics
An analysis of the phospho-tyrosine substrate network was performed on the IL-3independent WT TNK1-, TNK1-AAA- and BCR-ABL-driven Ba/F3 cells. These cells were
compared to control Ba/F3 cells that had been withdrawn from IL-3 for 24 hours to establish a
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baseline level of global phospho-tyrosine. Quantitative phospho-tyrosine proteomics was
performed by the Duke University School of Medicine Proteomics and Metabolomics Shared
Resource. Briefly, 2x108 Ba/F3 cells were collected and rinsed with ice-cold PBS. Cell pellets
were flash-frozen and sent to the Duke Proteomics Core Facility (DPCF). After addition of urea,
cell pellets were subjected to three rounds of probe sonication for 5 sec each with an energy setting
of 30%. Samples were then centrifuged at 12,000xg at 4oC for 5 min. Protein concentrations were
determined by Bradford assay. 10 mg of each sample were normalized with 8 M urea and then
diluted to 1.6 M urea with 50 mM ammonium bicarbonate. All samples were then reduced for 45
min at 32oC with 10 mM dithiolthreitol and alkylated for 30 min at room temperature with 25 mM
iodoacetamide. Trypsin was added to a 1:50 ratio (enzyme to total protein) and allowed to proceed
for 18 hr at 32oC. Samples were then acidified with TFA and subjected to C18 SPE cleanup (SepPak, 500 mg bed). Following elution, all samples were then lyophilized to dryness then
resuspended in PBS. Samples were subjected to immunoaffinity purification and enriched for
tyrosine phosphopeptides using PTMScan (Cell Signaling Technology), then lyophilized. At this
point, the sample was subjected to simple TiOx enrichment after being spiked with a total of either
2.5 or 5 pmol of casein for internal standard quality control, then lyophilized again. Samples were
resuspended in 12 μL 1%TFA/2% acetonitrile with 10 mM citrate containing 12.5 fmol/μL yeast
alcohol dehydrogenase (ADH_YEAST). From each sample, 2 μL was removed to create a QC
Pool sample which was run periodically throughout the acquisition period.

TiO2 phospho-proteomics
HEK293T cells were transfected with either FLAG-TNK1 WT or FLAG-TNK1-∆UBA
with PEI. 48hours post transfection, cells were harvested and lysed as descried above. All buffers
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were prepared with HPLC-grade-water. Clarified lysate were incubated with ANTI-FLAG® M2
Affinity Gel for 1hour in 4oC. Resin were washed with cold PBS supplemented with protease and
phosphatase inhibitors twice and then three times with Ambic solution (50mM ammonium
bicarbonate in water). The proteins were eluted with elution buffer (0.25% rapigest SF in 50mM
ammonium bicarbonate) and boiled for 3 mins. Samples were flash-freeze and sent to the Duke
Proteomics Core Facility (DPCF) for further preparation. Samples were prepared for in-solution
digestion, TiOx enrichment and LC-MS/MS Analysis as described above
Quantitative LC-MS/MS Analysis
Quantitative LC-MS/MS was performed on 4 μL of each Ba/F3 tyrosine phosphopeptide
sample, using a nanoAcquity UPLC system (Waters Corp) coupled to a Thermo Orbitrap Fusion
Lumos high resolution accurate mass tandem mass spectrometer (Thermo) via a nanoelectrospray
ionization source. Briefly, the sample was first trapped on a Symmetry C18 20 mm × 180 μm
trapping column (5 μl/min at 99.9/0.1 v/v water/acetonitrile), after which the analytical separation
was performed using a 1.8 μm Acquity HSS T3 C18 75 μm × 250 mm column (Waters Corp.) with
a 90-min linear gradient of 3 to 30% acetonitrile with 0.1% formic acid at a flow rate of 400
nanoliters/minute (nL/min) with a column temperature of 55oC. Data collection on the Fusion
Lumos mass spectrometer was performed in a data-dependent acquisition (DDA) mode of
acquisition with a r=120,000 (@ m/z 200) full MS scan from m/z 375 – 1500 with a target AGC
value of 2x105 ions. MS/MS scans were acquired at Rapid scan rate (Ion Trap) with an AGC target
of 5x103 ions and a max injection time of 200 ms. The total cycle time for MS and MS/MS scans
was 2 sec. A 20 sec dynamic exclusion was employed to increase depth of coverage. The SPQC
pool containing an equal mixture of each sample was analyzed after every 4 samples throughout
the entire sample set.
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Next, data were imported into Proteome Discoverer 2.3 (Thermo Scientific Inc.) and all
LC-MS/MS runs were aligned based on the accurate mass and retention time of detected ions
(“features”) which contained MS/MS spectra using Minora Feature Detector algorithm in
Proteome Discoverer. Relative peptide abundance was calculated based on area-under-the-curve
(AUC) of the selected ion chromatograms of the aligned features across all runs. Peptides were
annotated at a maximum 1% peptide spectral match (PSM) false discovery rate.
The MS/MS data were searched against the SwissProt M. musculus database (downloaded
in Apr 2018) and an equal number of reverse-sequence “decoys” for false discovery rate
determination. Mascot Distiller and Mascot Server (v 2.5, Matrix Sciences) were utilized to
produce fragment ion spectra and to perform the database searches. Database search parameters
included fixed modification on Cys (carbamidomethyl) and variable modifications on Meth
(oxidation); Asn/Gln (deamidation); Ser/Thr/Tyr (phosphorylation).

TNK1 WT and ∆UBA Phospho-Proteomics
HEK293T cells were transfected with either FLAG-TNK1 WT or FLAG-TNK1 ∆UBA
with PEI. 48 hours post-transfection, cells were harvested and lysed as descried above. All buffers
were prepared with HPLC-grade water. Clarified lysate were incubated with ANTI-FLAG M2
Affinity Gel (Simga Aldrich) for 1 hour at 4oC. Resins were washed with cold PBS supplemented
with protease and phosphatase inhibitors twice and then with Ambic solution (50 mM ammonium
bicarbonate in water) three times. The proteins were eluted with elution buffer (0.25% rapigest SF
in 50 mM ammonium bicarbonate) and boiled for 3 mins. Samples were flash-frozen and sent to
the Duke Proteomics Core Facility (DPCF) for further preparation. Samples were prepared for insolution digestion, TiOx enrichment and LC-MS/MS analysis as described above.
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Confocal
pEGFP-N1-FLAG was a gift from Patrick Calsou (Addgene plasmid # 60360). TNK1 was
cloned into pEGFP-N1-FLAG plasmid, so that the EGFP tag is C-terminal to TNK1. HEK293A
cells were seeded on coverslips and transfected with appropriate constructs. The next day, cells
were fixed with 4% PFA in PBS for 10 minutes and permeabilized with 0.1% Triton X-100 (in
PBS). Cells were blocked using Seablock Blocking Buffer (ThermoFisher Scientific) at room
temperature for 1 hour. Primary antibodies were added in diluted blocking buffer (10% Seablock
Blocking Buffer in PBS with 0.1% Tween) overnight at 4°C. Coverslips were washed 3 times with
PBS, and then incubated with Alexa Fluor-conjugated secondary antibodies at a 1:1000 dilution
in Seablock Blocking Buffer for 1 hour at room temperature. DAPI was added for the last 5 minutes
at a 1:100 dilution. Coverslips were then washed with PBST once followed by 2 washes with PBS.
Coverslips were mounted on slides using ProLong Diamond Antifade Mountant (ThermoFisher
Scientific) and cured for 24 hours before imaging. Imaging was performed using Leica TCS SP8
DMi8 confocal laser microscope using at 63X oil-immersion lens. After acquisition, images were
processed using Huygens Deconvolution software and Leica 3D analysis software. Image channels
were acquired sequentially using appropriate settings for DAPI, eGFP, and Alexa Fluor 663.
Representative images are shown within figures. Quantification was performed by counting 50
cells per slide and condition visually for phenotype, designated as punctuate or diffuse. In all
experiments, images shown within panels were all acquired using identical intensity and exposure
time at room temperature.
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14-3-3ζ-TNK1 FRET Assay
The FRET assay was performed as adapted from Du. et. al., 2013. Briefly, His-14-3-3ζ (12
nM final, R&D Systems); Cy5-TNK1, Cy5-p502-TNK1, or Cy5-p500/p502/p505-TNK1 (10 µM
final, 5 µM final, and 1 µM final for each peptide; New England Peptide); Europium-anti-His
antibody (0.75 nM final, PerkinElmer), and Bovine Serum Albumin (2 µg) were added to FRET
buffer (20 mM Tris, pH 7.4, 0.1% Nonidet P40 and 50 mM NaCl; adapted from Du et. al. 2013)
for a final volume of 30 µL per reaction. Negative control reactions were performed as half the
reactions without 14-3-3ζ to determine background fluorescence transfer. For the positive control
reactions, Cy5-p136-BAD (12.5 µM final, New England Peptide), a known 14-3-3ζ interacting
partner, was added instead of TNK1. The assay was performed in a black, flat-bottom, 384-well
plate (Corning), with reactions done in quadruplicate. The plate was covered and incubated for 2
hours at room temperature. Then, the fluorescence was measured using the PerkinElmer EnVision
Multimode plate reader, excitation: 340 nm, emission: 615 nm and 665 nm. FRET ratios were
determined by dividing the 615 nm fluorescence value by the 665 nm fluorescence value, and
multiplying by 103. Peptide sequences were as follows:
Cy5-TNK1 Sequence: H2N-(C/Cy5Mal)RMKGISRSLESVLSLGP-amide;
Cy5-p502-TNK1 Sequence: H2N-(C/Cy5Mal)RMKGISR(pS)LESVLSLGP-amide;
Cy5-p500/p502/p505-TNK1 Sequence: H2N-(C/Cy5Mal)RMKGI(pS)R(pS)LE(pS)VLSLGPamide;
Cy5-p136-BAD Sequence: H2N-(C/Cy5Mal)LSPFRGRSR(pS)APPNLWA-OH
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Development of TNK1 inhibitor – TP-5801
The active site of the TNK1 homology model was built using an ALK crystal structure
(PDB code 4MKC) as a template (ICM-Pro, Molsoft). TP-5801 was designed using computational
chemistry techniques based on initial diaminopyrimidine “hit” compounds from an in-house
library, which was screened in a biochemical assay against a truncated recombinant TNK1
(encompassing the kinase domain).

Tumor progression study in mice
1x106 Ba/F3 luc cells expressing vector (pMIG), WT TNK1, TNK1 mutants (as indicated),
or BCR-ABL were injected into the tail vein of both male and female NOD/SCID mice (n=5 for
each group). Mice were imaged in both prone and supine position using an IVIS Spectrum in vivo
imaging system (Perkin Elmer). Bioluminescent signals were quantified using Living Image 4.3.1
(Caliper Life Sciences). Signals were analyzed by region of interest (ROI) analysis, which
measured total body flux (photons/second) over time. Moribund animals were sacrificed as per
IACUC guidelines. Survival data were analyzed using Kaplan-Meier method, and statistical
significance was evaluated with a Log-rank test (GraphPad PRISM) comparing the survival time
of each group.
Drug study on tail vein-injected mice
1x106 Ba/F3 luc cells expressing TNK1 AAA were injected into the tail vein of female
NOD/SCID mice. (n=5 for each group). 3 days after injection, mice were treated once daily by
oral gavage with vehicle (0.5% Methylcellulose (w/v), 0.5% Tween 80 (v/v), 99% H2O (v/v)) or
TP5801 (10 mg/kg). Moribund animals were sacrificed as per IACUC guidelines. Survival data
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were analyzed using Kaplan-Meier method, and statistical significance was evaluated with a Logrank test (GraphPad PRISM) comparing the survival time of each group.

Drug study on Sub-Q mice
1x106 Ba/F3 luc cells expressing TNK1-AAA were implanted subcutaneously into the
flank of NOD/SCID mice. Mice were randomized to treatment groups (n=10) when the average
tumor volume reached approximately 100-200 mm3. Mice were treated once daily by oral gavage
with vehicle (0.5% Methylcellulose (w/v), 0.5% Tween 80 (v/v), 99% H2O (v/v)), or TP5801 (50
mg/kg) for up to 7 consecutive days. Bioluminescent signals were imaged, quantified, and
analyzed as mentioned above. Mice were sacrificed and tumor samples were collected. Tumor
samples were weighed. Some tumor samples were flash frozen and some were paraffin embedded.

In vitro kinase screen
The abilities of 245 individual Ser/Thr kinases to phosphorylate a TNK1 peptide that
includes S502 were evaluated using a radiometric KinaseFinder assay (ProQinase GmbH). A
biotinylated peptide (Biotin-RMKGISRSLESVL-OH; New England Peptide) was reconstituted in
50 nM HEPES pH 7.5 at 200 µM stock solution. Reaction buffer (60 mM HEPES-NaOH pH 7.5,
3 mM MgCl2, 3 mM MnCl2, 3 µM Na-orthovanadate, 1.2 mM DTT, 1 µM ATP/[γ-33P]-ATP),
protein kinase (1-400 ng/50 µL) and TNK1 peptide (1 µM) were pipetted into 96-well, V-shaped
polypropylene microtiter plates (assay plate). All PKC assays (except the PKC-mu and the PKCnu assay) additionally contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml phosphatidylserine and 1
μg/ml 1.2-dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4,
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CAMKK2, and DAPK2 assays additionally contained 1 μg/ml calmodulin and 0.5 mM CaCl2.
The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. One well of each assay plate
was used for a buffer/substrate control containing no enzyme. The assay plates were incubated at
30°C for 60 minutes. Subsequently, the reaction cocktails were stopped with 20 μl of 4.7 M
NaCl/35 mM EDTA. The reaction cocktails were transferred into 96-well streptavidin-coated
FlashPlate® HTS PLUS plates (PerkinElmer, Boston MA), followed by 30 min incubation at room
temperature on a shaker to allow for binding of the biotinylated peptides to the streptavidin-coated
plate surface. Subsequently, the plates were aspirated and washed three times with 250 µl of 0.9%
NaCl. Incorporation of radioactive

33

Pi was determined with a microplate scintillation counter

(Microbeta, Perkin Elmer). For evaluation of the results of the FlashPlate® PLUS-based assays,
the background signal of each kinase (w/o biotinylated peptide) was determined in parallel. 7
protein kinases were selected from the screen described above to repeat at three peptide
concentrations (1 µM, 0.5 µM and 0.25 µM) in triplicate. The assays were performed as described
above.

In vitro IC50 of TP5801
Compounds were tested at Reaction Biology in 10-dose IC50 mode with a 3-fold serial
dilution in DMSO starting at 1-10 μM. Reactions were carried out at Km ATP for each enzyme (5
µM for TNK1, 10 µM for Aurora A, 50 µM for ALK) and includes 33-P labeled ATP. Resulting
% Enzyme activity (relative to DMSO controls) were plotted in GraphPad and IC50 values were
determined by sigmoidal dose-response (variable slope) curve fits, bottom constraint of 0.

NanoBRET Target Engagement Assay
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Transiently transfect TNK1-Nano-Luc Fusion vector DNA into HEK293 cells with
FuGENE HD Transfection Reagent. After 24 hours, cells are transferred into 384-well NBS plates,
where NanoBRET Tracer K5 reagent with final concentration of 0.125µM was delivered to cells.
The cells were then incubated at 37oC with 5% CO2 for 1 hour. After incubation, the plate was
removed from incubator and equilibrated to room temperature for 15 minutes. Complete substrate
plus inhibitor were added to the cells. Cells were incubated at room temperature for 2-3 minutes.
Donor emission wavelength (460nm) and acceptor emission wavelength (600nm) were measured
using the Envision 2104 plate reader. Bret ratio is defined by acceptor sample divided by donor
sample with background correction.

2.4. Results
RNAi kinome screen identifies TNK1-dependence in a subset of hematological
cancers.
With the goal of identifying tyrosine kinase dependencies in primary cancers, 435 human
patient samples were collected for ex vivo culture. These samples represented a variety of
hematological cancers, including acute myeloid leukemia (AML), B-cell and T-cell acute
lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). The samples were
cultured and subjected to a high throughput RNAi screen of the tyrosine kinome, followed by cell
viability assays (Supplemental. Figure 2-1A). RNAi targets that decreased cell viability by at least
two standard deviations below the mean were scored as positive hits. ‘Top hits’ were defined as
the kinase that, when depleted, had the largest negative impact on cell survival in a given sample.
Predictably, among the most frequently identified top hits were well-described oncogenic tyrosine
kinases, such as JAK1, JAK3, FLT3 and CSF1R. However, we unexpectedly identified TNK1 as
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a top hit in a subset of ALL and AML samples (Supplemental. Figure 2-1B-C). Furthermore, in
support of a link between TNK1 and ALL, we found a significant correlation between high TNK1
expression and decreased overall survival and relapse free survival in ALL patients (Supplemental.
Figure 2-1D). Given a general lack of understanding of TNK1 function and regulation, we decided
to probe deeper into TNK1 biology.
Truncations reveal a cluster of phosphorylations within the proline rich domain
that are required for 14-3-3 binding.
To begin to uncover the function and regulatory mechanisms of TNK1, we identified TNK1interacting proteins by BioID (BirA fused to the TNK1 C-terminus) and direct co-IP (FLAGTNK1), followed by LC-MS/MS (Supplemental. Figure 2-2A-E). Both approaches revealed an
abundance of the phospho-binding protein 14-3-3. Indeed, all 14-3-3 isoforms (β, γ, ε, ζ, θ, τ)
except sigma were identified as putative TNK1-interacting partners from both approaches
(Supplemental. Figure 2-2A). The TNK1-14-3-3 interaction was validated by co-IP and
immunoblotting with a 14-3-3 antibody (Supplemental. Figure 2-2B). Furthermore, TNK1 failed
to co-IP with a phospho-binding defective 14-3-3 (K49Q), indicating that the TNK1-14-3-3
interaction is mediated by phosphorylation(s) on TNK1 (Supplemental. Figure 2-2F).
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Figure 2-1. Phospho-Proteomics reveals a cluster of phosphorylations within the prolinerich domain of TNK1 and phosphorylation at S502 is required for 14-3-3 binding.
(A) Schematic diagram of wild type (WT) TNK1 and our panel of TNK1 truncations. FLAGTNK1 (WT or indicated mutants) were immunoprecipitated from HEK-293T cells and
immunoblotted for 14-3-3. Graph shows quantitation from multiple replicates with signals
normalized to WT. Error bars represent SEM.
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(B) HEK-293A cells expressing TNK1-GFP (WT or ∆UBA) were analyzed by confocal imaging
for TNK1 localization. Graph shows number of cells, counted manually, with diffuse or
punctate TNK1 localization (n=50).
(C) Schematic diagram of phosphorylations identified by TiO2 phospho-proteomics within the
proline-rich domain. Lower diagram shows an alignment of TNK1 sequence encompassing
pS502 (human numbering) from human to zebrafish.
(D) Graph (green bars) shows the number of recorded observations of S/T phosphorylations on
TNK1 via high-throughput methods (data derived from phosphosite.org) and the predicted
disorder (cyan lines; ANCHOR score derived from https://iupred2a.elte.hu) across the
sequence of TNK1.
(E) WT and mutant FLAG-TNK1 were immunoprecipitated from HEK-293T cells and
immunoblotted for TNK1 phosphorylation at S502 and 14-3-3. Graphs show quantitation of
infrared signal from multiple replicates with signals normalized to WT. Error bars represent
SEM.
(F) WT and mutant FLAG-TNK1 were immunoprecipitated from HEK-293T cells and
immunoblotted for 14-3-3. Graphs show quantitation of infrared signal from multiple
replicates with signals normalized to WT. Error bars represent SEM.
To identify the phosphorylations on TNK1 that trigger 14-3-3 binding, we first put the
TNK1 sequence through 14-3-3 site prediction algorithms (compbio.dundee.ac.uk/1433pred/),
which predicted several candidate phosphorylation sites within loose 14-3-3 consensus motifs,
including S60, S68, T392, S170, T401 and S434. However, none of the single S-to-A mutations
at these sites had any measurable effect on 14-3-3 binding (selected mutants shown in
Supplemental. Figure 2-3A). Therefore, we turned to deletion mapping, focusing first on known
domains situated on the C-terminal side of the kinase domain, including the SH3, proline-rich and
UBA domains. This approach mapped a 14-3-3-binding region to the proline-rich domain (Figure
2-1A). Interestingly, the UBA-deleted TNK1 construct (1-580 or “∆UBA”) not only retained 143-3 binding, but also showed an approximate 4-fold increase in interaction with 14-3-3 compared
to WT TNK1 (Figure 2-1A). Furthermore, we noted that deletion of the UBA resulted in a
markedly different localization pattern for TNK1—with WT TNK1 mostly forming large
perinuclear puncta and TNK1 ∆UBA showing a diffuse cytosolic pattern (Figure 2-1B). Together,
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these data were a first hint of interplay between the UBA domain and 14-3-3 binding, which we
revisit further below.

Figure 2-2. MARKs mediate TNK1 phosphorylation and 14-3-3 binding, which sequesters
TNK1 away from cytosolic puncta.
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(A) Radiometric protein kinase assays were performed to identify the kinase responsible for
phosphorylation of TNK1 at S502. Corrected kinase activity (raw value minus sample
peptide background) was measured in triplicate. Graph shows mean kinase activity in counts
per minute (cpm) with error bar representing standard deviation.
(B) HEK293Ts expressing FLAG-TNK1 were treated with 1uM of indicated inhibitor for 4 hours
(MARKi: MRT 67307 dihydrochloride, CaMKKi: STO-609, CaMKIIi: KN-92, KN-93,
RSKi: LJI-308, IKKi: BMS 345541). FLAG-TNK1 was immunoprecipitated and blotted for
pS502 and 14-3-3 binding. Graphs show quantitation normalized to WT TNK1. Error bars
represent SEM.
(C) MARK kinases were depleted with siRNA (100nM) in A549 cells stably expressing FLAGTNK1. FLAG-TNK1 was immunoprecipitated on FLAG resin and immunoblotted for pS502
and 14-3-3.
(D) (Left) Alignment of TNK1 sequence encompassing pS502 to a MARK-phosphorylated 14-33 binding site on PAR3a. (Right) Schematic model of MARK-mediated phosphorylation of
TNK1 at S502 and 14-3-3 binding.
(E) HEK-293A cells express TNK1-GFP (WT or indicated mutants) were analyzed by confocal
imaging for diffuse or punctate TNK1 localization and deconvolved with Hyugens software.
TNK1 ∆UBA-expressing cells were treated with 1 uM MARK inhibitor (MRT 67307).
(F) Cells from panel E were analyzed for TNK1 puncta volume using Leica 3D analysis.
(G) Cells from panel E were scored for diffuse and punctate TNK1 localization as in figure 1B.
(H) HEK-293T cells expressing WT or the indicated mutants of FLAG-TNK1 were
biochemically fractionated into cytosol and heavy membrane fractions, followed by
immunoblotting for FLAG - TNK1. Fractions were also immunoblotted for Bak and actin as
loading controls.
(I) The graph shows the relative HM/C ratio normalized to WT TNK1 from (H). Quantitation is
from multiple replicates with error bar representing SEM.
First, given our co-IP results in Figure 2-1A, we reasoned that 14-3-3 docking site
phosphorylations, likely within the proline-rich domain, should be elevated on TNK1 ∆UBA (1580) compared to WT TNK1. As shown in Figure 2-1C, TiO2 phospho-proteomics revealed a
cluster of phosphorylations within the proline-rich domain at S500, S502 and S505 enriched on
UBA-truncated TNK1. All three phosphorylations are catalogued at phosphosite.org as previously
identified in high-throughput mass spectrometry (MS), but have no annotated function. Based on
these unbiased aggregated MS studies, pS502 is the most frequently identified S/T phosphorylation
across the entire sequence of TNK1 (Figure 2-1D). In addition, this cluster of phosphorylations
lies within the region of TNK1 that scores highest for predicted disorder (Figure 2-1D), which
suggests a protein-protein binding interface, particularly noted for other 14-3-3 binding sites 68-70.
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We found that single S-to-A mutations at S500 and S505 partially reduce 14-3-3 binding to TNK1,
whereas mutation at S502 had a more dramatic effect, reducing 14-3-3 binding to near-background
levels (Figure 2-1E). 14-3-3 binding was completely eliminated by mutation of all three sites—
referred to here as “TNK1 AAA” (Figure 2-1F).
We were initially puzzled by the requirement of such a tightly packed cluster of three
phosphorylations for 14-3-3 binding. The phospho-binding groove of a 14-3-3 monomer only
accommodates a single phosphorylation, and within a 14-3-3 dimer, the grooves are ~34 angstroms
apart

48

. Initially, we reasoned that phosphorylations within this cluster may be required for

phosphorylation at a distant 14-3-3 docking site. In this scenario, phospho-mimicking substitutions
S500/502/505 should induce 14-3-3 binding. However, we found that S500E/S502E/S505E
mutants are as effective at abrogating 14-3-3 binding as the phospho-null S-to-A mutations
(Supplemental. Figure 2-3B), which is commonly observed for 14-3-3-docking site
phosphorylations (Glu and Asp fail each to satisfy the chemistry of the 14-3-3 phospho-binding
groove). We then questioned whether this cluster of three phosphorylations represents a noncanonical mode of 14-3-3 binding. In a FRET-based 14-3-3-binding assay, we only detected 143-3 binding to a mono-phosphorylated pS502 TNK1 peptide at levels comparable to our positive
control, phospho-BAD (Supplemental. Figure 2-3C). Importantly, we did not detect any
appreciable binding to the triple-phosphorylated pS500/pS502/pS505 peptide nor to a nonphosphorylated TNK1 peptide control (Supplemental. Figure 2-3C). Together, these data suggest
that phosphorylation at S502 is sufficient for 14-3-3 binding in a canonical manner, but leave open
the possibility of redundancy between the sites, a sequential requirement for phosphorylation at
one site to precede another, or perhaps, most likely, that S500 and S505 are required for docking
of the kinase to phosphorylate S502.
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The sequence surrounding pS502 is a relatively poor match to consensus sequences of
kinases commonly reported to phosphorylate 14-3-3 binding sites, such as PKB, PKC, AMPK and
CAMKII 48. Our targeted efforts to test these and other candidate kinases as regulators of pS502
did not reveal any compelling hits (data not shown). To expand our search, we generated a biotintagged peptide encompassing the S502 site and performed radiometric kinase assays with 245
individual human kinases that span the majority of Ser/Thr kinase subfamilies. Only two kinase
subfamilies, Ca2+/calmodulin-dependent kinases (CAMKs) and microtubule affinity-regulating
kinases (MARKs), showed significant reactivity toward the S502 sequence, with MARKs as the
top hit (Figure S3D-H and Figure 2A). Subsequent kinase inhibitor experiments in cells indicated
that MARKs, but not CAMKII, phosphorylate S502 (Figure 2-2B).
MARKs (MARK1-4) are members of the AMPK family and, like AMPK, are activated
downstream of the tumor suppressor LKB1

71, 72

. They were initially named for their role in

regulating microtubule dynamics to control dendrite growth and cell motility 73. Genetic studies
indicate some redundancy among the different MARKs74 and, importantly, some MARK
substrates have been shown to interact with 14-3-3 75, 76. For example, the phosphorylation site that
mediates 14-3-3-binding on one MARK substrate, Par3a, is similar to the sequence surrounding
pS502: KSS[pS]LES on Par3a compared to ISR[pS]LES on TNK1—both of which differ from the
loose consensus for 14-3-3 binding sites with neither an Arg nor Pro in the -3 and +2 positions,
respectively 48. To test this idea further, we depleted cells of individual MARK isoforms and found
that knockdown of MARK4 reduces pS502 and 14-3-3 binding to TNK1 (Figure 2-2C-D).
Phosphorylation of TNK1 and 14-3-3 binding restrain the movement of TNK1 into
heavy membrane-associated clusters.
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To begin to understand what effect the MARK-mediated 14-3-3 interaction has on TNK1,
we compared the localization of WT and AAA mutant TNK1. Confocal imaging showed that loss
of 14-3-3 binding, caused by the AAA mutation, triggers TNK1 to consolidate into punctate
structures within the cytosol (Figure 2-2E-G). This effect is particularly pronounced with TNK1
∆UBA, which moves dramatically from diffuse to punctate upon mutation of the 14-3-3 docking
site (Figure 2-2E and G). Importantly, we found that inhibition of MARK kinase activity
completely reproduced the effect of the AAA mutation in causing TNK1 ∆UBA to contract into
distinct cytosolic puncta (Figure 2-2E and G), further supporting the idea that MARKs govern
TNK1 via phosphorylation at S502 and consequent control of 14-3-3 binding.
In an effort to validate our confocal imaging observations through biochemical methods, we
found that the bulk of WT TNK1 was found in a 1% Triton X-100-soluble heavy membrane (HM)
fraction. In contrast, deletion of the UBA shifted TNK1 into the cytosolic (C) fraction (Figure 22H-I), reflecting the diffuse pattern of localization observed by confocal imaging (Figure 2-2E).
Remarkably, consistent with imaging data in figure 2E, disruption of 14-3-3 binding caused an
accumulation of full-length TNK1 and TNK1 ∆UBA in the HM fraction. Together, these data
suggest that MARK-mediated phosphorylation of TNK1 and 14-3-3 binding sequester TNK1 in
the cytosol, preventing TNK1 movement into heavy membrane-associated clusters.
TNK1 contains a high affinity UBA domain that interacts with multiple ubiquitin
linkages.
These initial observations—that deletion of the TNK1 UBA domain increases TNK1
interaction with 14-3-3 and affects its localization— led us to investigate the TNK1 UBA. To the
best of our knowledge, TNK1 and ACK1 are the only known human tyrosine kinases with
predicted UBA domains. Thus, we questioned whether the TNK1 UBA acts conventionally,
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through binding ubiquitin, or plays some other ubiquitin-independent role in kinase regulation
(e.g., like AMPK UBAs). As shown in Figure 2-3A, WT TNK1 co-immunoprecipitated from cells
with a range of ubiquitinated species, which were lost with TNK1 ∆UBA, suggesting that TNK1
has a functional UBA domain.

Figure 2-3. TNK1 possesses a functional UBA at its C-terminus and the ubiquitin binding
properties of the TNK1 UBA are essential for TNK1 activity and TNK1-driven cell
proliferation.
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(A) WT or ∆UBA FLAG-TNK1 were immunoprecipitated from HEK-293T cells and
immunoblotted for ubiquitin binding. Graphs show quantitation from multiple replicates with
signals normalized to WT. Error bars represent SEM.
(B) Recombinant GST-TNK1-UBA or GST-TAB2-UBD were incubated with individual tetraubiquitin chains of various linkages at 4oC for 2 hours. GST-tagged proteins were captured
on glutathione resin and immunoblotted for GST and ubiquitin.
(C) Recombinant GST-TNK1-UBA or GST-TAB2-UBD were incubated with a cocktail of
mono-ubiquitin together with either K48- or K63-linked poly-ubiquitin of chain lengths 2-7.
Captured GST-proteins were immunoblotted as in panel B.
(D) A table summary showing average measured Kd of TNK1-UBA/TAB2 UBD towards
K48/K63 linked tetra-ubiquitin using Bio-layer interferometry (BLI). Errors representing
standard deviation of the measured Kd.
(E) The diagram shows a Rosetta-modeled structure of TNK1 UBA domain and a homology
model-based prediction of the binding interfaces between the UBA and ubiquitin.
(F) Recombinant GST-tagged WT and mutant TNK1 UBA were incubated with either K48 or
K63 tetra-ubiquitin. The GST-UBA was captured and immunoblotted as in panel B.
(G) Ba/F3 cells were transduced with retrovirus expressing either the pMIG-empty vector, WT
TNK1, the indicated TNK1 mutants or BCR-ABL. IL-3 independent growth was monitored
by IncuCyte live cell imaging. Error bars represent SEM.
(H) Confocal analysis of TNK1-GFP (WT or indicated mutants) in HEK-293A cells as in figure
2-1 panel B.
To test the ubiquitin binding specificity of the TNK1 UBA in a cell free system, we
produced a GST-tagged recombinant TNK1 UBA and measured its binding to various linkages of
tetra-ubiquitin (K6-, K11-, K29-, K33-, K48-, K63- and M1-linked). The TNK1 UBA interacted
with all linkage types tested (figure 2-3B). As a control, a GST-tagged ubiquitin-binding domain
from TAB2 (TAB2 UBD) showed specificity for K63-linked chains (figure 2-3B), as previously
reported77. Next, we took advantage of the different electrophoretic mobilities of K48-, K63- and
M1-linked chains and measured their binding to TNK1 UBA in a mixed, competition-based pulldown assay. Again, the TNK1 UBA showed no apparent preference for linkage type, whereas the
TAB2 UBD selectively pulled down K63-linked ubiquitin from the mixture (sup. figure 2-4A).
We also observed robust interaction between the TNK1 UBA and K63- or K48-linked polyubiquitin of variable chain lengths (Ub2-7), but were unable to observe any interaction with monoubiquitin (figure 2-3C).
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Despite adding equimolar concentrations of ubiquitin chains to the pulldown assays in
figures 2-3C and sup. figure 2-4A, their interpretation by immunoblot is complicated because
ubiquitin antibodies often show preference for K63-linked chains77. Therefore, we analyzed the
GST-tagged TNK1 UBA and TAB2 UBD by biolayer interferometry (BLI) with purified K48and K63-linked tetra-ubiquitin chains to measure dissociation constants (Kd). For the TNK1 UBA,
we observed a Kd of 0.5 nM for K63-linked ubiquitin and a comparatively lower affinity for K48linked ubiquitin with a Kd of 2.35 nM (figure 2-3D and sup. figure 2-4B). Both affinity
measurements place the TNK1 UBA at the lower range of observed dissociation constants for
UBA domain interactions with tetra-ubiquitin 78-80, indicating a tight interaction between the TNK1
UBA and structurally diverse ubiquitin linkages. For comparison in our assays, the TAB2 UBD
showed a Kd of 170 nM for K63-linked ubiquitin—similar to the previously published Kd for
TAB2 UBD81 — but had no detectable affinity for K48-linked chains (figure 2-3D and sup. figure
2-4B).
To further characterize the TNK1 UBA and develop tools to understand the relationship
between ubiquitin binding, 14-3-3 binding and TNK1 kinase activity, we looked for residues
within the TNK1 UBA that interface with ubiquitin. There is no published crystal structure of fulllength TNK1 and our attempts to purify TNK1 were unsuccessful, likely due to a large region of
predicted intrinsic disorder between the SH3 domain and the UBA. Computational modeling of
the TNK1 UBA domain suggests homology between the TNK1 UBA and published crystal
structures of other UBA domains. Therefore, we submitted the putative TNK1 UBA domain amino
acid sequence (residues 590 - 666) to the Robetta server for structure prediction via Rosetta
homology modeling 82. The closest match, according to primary sequence and predicted secondary
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structure, is the UBA domain of the ubiquitin-associated protein 1 (UBAP1) subunit of ESCRT-I,
a seven-helix bundle 83.
Our homology modeling (see materials and methods for details) suggested potential
ubiquitin-binding interfaces within helices 1 and 3 of the TNK1 UBA (Figure 2-3E). However,
point mutations in helix 1 at M596 and L600 had no effect on TNK1-ubiquitin binding. In contrast,
mutations at I625 and L636 in helix 3 abolished the interaction with ubiquitin. Notably, a mutation
at F634, also within helix 3 (but not predicted to directly interface with ubiquitin in our model),
disrupted the interaction with K48-linked ubiquitin, but had no effect on K63-linked chains (Figure
2-3F).
The uniqueness of a kinase possessing a high-affinity and indiscriminate UBA domain
raised our interest in the role the UBA might play in regulating TNK1 kinase activity. TNK1 was
previously identified in a retroviral screen for tyrosine kinases that transform the normally IL-3dependent pro-B cell line, Ba/F3, to growth factor independence31. Consistent with their results,
we found that retrovirus-expressed WT TNK1 transformed Ba/F3s to IL-3-independence within
5-7 days (Figure 2-3G). However, the helix 3 mutations that completely disrupted ubiquitin
binding, abolished TNK1-mediated transformation of Ba/F3s, whereas F634D, which only
partially inhibited ubiquitin binding, likewise partially delayed transformation (Figure 2-3F-G).
Consistent with these results, we found that any mutation that disrupts ubiquitin binding also
reduces TNK1 kinase activity, as measured by global phospho-tyrosine levels (Supplemental.
Figure 2-4C, quantitation in Supplemental. Figure 2-4E). Furthermore, the loss of ubiquitin
binding and TNK1 activity correlated with increased binding of TNK1 to 14-3-3 and a diffuse
localization across the cytosol (Figure 2-3H and Supplemental. Figure 2-4D), which is consistent
with what we observed for TNK1 ∆UBA (Figure 2-1A-B). As quantified in Figure S4E, this
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inverse relationship between 14-3-3 binding and TNK1 activity suggests that phosphorylation at
S502 and 14-3-3 binding may inhibit TNK1 kinase activity.

Figure 2-4. Loss of 14-3-3 binding activates TNK1 and unleashes TNK1-driven tumor
growth in vivo.
(A) Ba/F3 or FDCP1 cells were transduced (as in Figure2- 4) with either pMIG-empty vector,
TNK1 (WT or indicated mutants) or BCR-ABL. IL-3 independent growth was monitored as
in Figure 2-3 panel G.
(B) Ba/F3 cells from panel A were immunoblotted for global phospho-tyrosine and GFP. Graphs
show global tyrosine phosphorylation quantitation from multiple replicates with signals
normalized to WT. Error bars represent SEM.
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(C) 1x106 Ba/F3-luc cells transduced with WT TNK1 or the indicated TNK1 mutants were
injected into the tail vein of NOD/SCID mice. Luminescent signal was imaged and quantified
using IVIS imaging and ROI analysis. Images shown are mice in prone position 28 days after
injection.
(D) Corrected Flux (raw luminescent signal minus background luminescent signal) of mice from
panel C.
(E) Survival plot of mice from panel C.
Full activation of TNK1 requires release from 14-3-3 and interactions between
the TNK1 UBA and ubiquitin.
To begin to disentangle the effect of 14-3-3 and ubiquitin binding on TNK1 activity, we
transduced Ba/F3 cells and a similarly IL-3-dependent myeloid progenitor line, FDC-P1, with
retroviruses expressing our panel of TNK1 mutants, including the 14-3-3-binding-defective TNK1
AAA mutant, followed by measurement of growth factor independence as in Figure 2-3G. The
potently oncogenic BCR-ABL served as a positive control84 . Remarkably, the TNK1 AAA mutant
induced growth factor independence almost immediately after IL-3 withdrawal, which was
comparable to the rapid transformation observed with BCR-ABL, both of which transformed cells
several days ahead of WT TNK1 (Figure 2-4A). This effect of TNK1 on Ba/F3s was completely
dependent on kinase activity, as a kinase-dead point mutation (K148R) abolished transformation
(Figure 2-4A).
Consistent with our observation that UBA-disrupting point mutations inhibit TNK1
activity, we found that TNK1 ∆UBA failed to promote growth factor independence (Figure 2-4A).
Interestingly, the combination of UBA deletion and AAA mutation only resulted in delayed
kinetics of transformation compared to the AAA mutation alone, yet it was still significantly more
potent than WT TNK1 in these assays (Figure 2-4A). The rate of transformation by each mutant
tracked with TNK1 kinase activity, such that TNK1 AAA showed the highest levels of global
phospho-tyrosine, while deletion of the UBA resulted in lower activity for WT TNK1 and the
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AAA mutant (Figure 2-4B). Nevertheless, TNK1 ∆UBA-AAA promoted significantly higher
levels of global phospho-tyrosine than TNK1 ∆UBA alone (Figure 2-4B). These results support
the idea that release of TNK1 from 14-3-3 is the critical step toward TNK1 activation and that
interactions between the UBA domain and ubiquitin, although important, play a secondary role in
driving TNK1 activity (see discussion for more detail).
The Hodgkin lymphoma (HL) cell line L540 carries a paracentric chromosomal inversion
that truncates TNK1 at D472, generating an active and highly expressed form of TNK1 32. Because
this truncation occurs just N-terminal to S502, it effectively eliminates the 14-3-3 binding site and
UBA, which yields a TNK1 protein similar to our TNK1 ∆UBA-AAA construct—both lacking
the 14-3-3 and UBA motifs. Indeed, expression of a D472-truncated TNK1 promotes growth
factor-independence in Ba/F3 cells with similar kinetics to TNK1 ∆UBA-AAA (Supplemental.
Figure 2-5A-B, compare to Figure 2-4A). Thus, our data provide a mechanistic explanation (i.e.,
loss of 14-3-3 binding) for why this naturally occurring truncation generates an active, oncogenic
form of TNK1.
To measure the ability of TNK1-driven Ba/F3 cells to grow in vivo, we stably integrated
luciferase into the parental Ba/F3 cells for bioluminescent imaging of tumor burden, followed by
retroviral expression of our panel of TNK1 variants and BCR-ABL. In a murine model, in which
mice were injected with Ba/F3 cells via the tail vein, we found that TNK1-AAA-driven cells
established rapid tumor burden and induced mortality with similar kinetics to BCR-ABL (Figure
2-4C-E). In contrast, mice injected with WT- and TNK1 ∆UBA-expressing cells showed no
detectable tumors nor physical signs of tumor burden (Figure 2-4C-E). Interestingly, TNK1
∆UBA-AAA cells established low levels of tumor burden, but cells were primarily confined to the
tail (Figure 2-4C) and were remarkably benign in this model (Figure 2-4D-E).
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Figure 2-5. Quantitative phospho-tyrosine proteomics reveals a TNK1-mediated network of
phospho-substrates.
(A) (Left) Schematic illustration of experimental design for phospho-tyrosine proteomics.
(Right) Heat map shows the hierarchical clustering analysis of all 2,294 phospho-tyrosine
peptides from three biological replicates of each sample.
(B) A focused heat map showing the relative phospho-tyrosine signal of selected significant
substrates across the different samples.
(C) Volcano plots of phosphorylation changes between the indicated samples. Selected phosphosubstrates are highlighted in red.
(D) Indicated Ba/F3 cells were immunoblotted for phosphor-PLCγ1 (Y284), total PLCγ1,
phosphor-STAT3 (Y705), total STAT3, phosphor-STAT5 (Y694), total STAT5 and β-actin.
Graphs show quantification from multiple replicates. Phosphorylation signals were
normalized to respective total protein signals. pSTAT3/STAT3 signals were normalized to
TNK1 WT. pSTAT5/STAT5 signals were normalized to BCR-ABL. Error bars represent
SEM.
- 45 -

Phospho-tyrosine proteomics reveals a network of TNK1-mediated phosphosubstrates.
The ability of TNK1-AAA and BCR-ABL to induce rapid growth factor-independence in
vivo, suggested they may be functioning through similar pathways despite differences in domain
architecture. The Ba/F3 cells provided a relatively clean isogenic system to evaluate the phosphotyrosine substrate networks of these kinases with minimal noise from other tyrosine kinases after
IL-3 withdrawal (Figure 2-5A, experimental layout).

Thus, to determine phospho-tyrosine

substrate networks for these kinases, we performed phospho-tyrosine enrichment and quantitative
LC-MS/MS. We found that WT TNK1 and TNK1-AAA showed similar phospho-tyrosine
profiles, but were markedly different than BCR-ABL, which can be visualized in the global
phospho-tyrosine heat map (Figure 2-5A). Indeed, an opposite phospho-tyrosine fingerprint
emerged for TNK1, relative to BCR-ABL, across a number of proteins, including multiple PI3K
subunits, PI4K, AMPK subunits, PLC-γ, TAB1, TBK1, NCK1, Rack1, STATs and others (Figure
2-5B). In addition, for TNK1 AAA relative to TNK1 WT, we saw an enrichment of phosphotyrosine substrates involved in ubiquitin processes (Supplemental. Figure 2-6A-B)85. Pairwise
comparisons of the kinases or kinases to mock are shown by volcano plot in Figure 2-5C.
Next, we selected a subset of phospho-tyrosine substrates from the proteomics data for
validation. An early study on TNK1 identified Phospholipase C-gamma (PLC-γ) as a TNK1
interacting partner, but the interaction had no clear function28. As shown in figure 2-5E, we found
that TNK1, but not BCR-ABL, phosphorylates PLC-γ at Y783, a phosphorylation known to
activate PLC-γ enzymatic activity while in complex with growth factor receptors

86, 87

. Another

potentially interesting divergence between TNK1 and BCR-ABL lies in STAT3 and STAT5 (see
Figure 2-5B, STAT panels). Consistent with the proteomics data, we found that TNK1 promoted
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an activating phosphorylation of STAT3, but not STAT5. Conversely, BCR-ABL triggered
phosphorylation of STAT5, but not STAT3 (Figure 2-5D). Accordingly, inhibition of STAT3 by
the clinical STAT3 inhibitor Niclosamide 88 blocked TNK1-driven cell growth, but had little effect
on BCR-ABL-driven growth (Supplemental. Figure 2-6C).
Development of a TNK1 inhibitor.
Collectively, our data implicated TNK1 as a potential therapeutic target. To identify
candidate anti-TNK1 compounds, we screened small molecule libraries for compounds with
activity against recombinant TNK1 in biochemical assays (Supplemental. Figure 2-7A). An
experimental compound, TP-5801, was designed based on initial hits in our biochemical screen.
TP-5801 aligns along the hinge of the protein, with the aryl bromo substituent orienting towards
the gate-keeper methionine residue. A single hydrogen bond is shown between the N1 of the
pyrimidine ring of TP-5801 and the backbone NH of L198 hinge residue. Major hydrophobic
interactions occur between the sidechain of L122, the backbone of G202 and the substituted phenyl
ring of TP-5801. The substituted pyridine ring of TP-5801 situates beneath the P-loop with the
dimethylamino group oriented towards the catalytic lysine, forming major hydrophobic
interactions with the sidechains of L252 (P-loop) and V130 (Figures 2-6A, Supplemental. Figure
2-7B). In vitro assays with purified kinases revealed IC50s of 1.40 nM against TNK1 compared to
5.38 uM against Aurora A kinase (Figure 2-6B). Nano-BRET analysis of TP-5801 indicated an
IC50 of 10.5 nM against TNK1 (Supplemental. Figure 2-7C). To transition to a cell-based system,
we used the TNK1-driven and BCR-ABL-driven Ba/F3 cell pair, which we verified to have
differential kinase dependency using the BCR-ABL inhibitor asciminib (Supplemental. Figure 27D). In Ba/F3 cells, TP-5801 potently inhibited TNK1-driven cell growth with IC50s of 77.8 and
37.0 nM against WT TNK1 and AAA mutant cells, respectively (Figure 2-6C). For comparison in
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the same model, TP-5801 inhibited BCR-ABL-driven and IL3-driven Ba/F3 cell growth with
IC50s of 8.5 and 1.2 µM respectively (Figure 2-6C, see Figure 2-6E for summary of IC50s).
Furthermore, as we would predict, low nM levels of TP-5801 blocked the growth of the TNK1dependent HL cell line, L540 (Figure 2-6D).

Figure 2-6. The development of a potent TNK1 inhibitor that reduces tumor burden and
extends life span in a TNK1-driven tumor model.
(A) The structure of TP-5801.
(B) In vitro IC50.
(C) IC50 graph of IL3 driven Ba/F3 cells, TNK1-WT/AAA driven Ba/F3 cells or BCR-ABLdriven Ba/F3 cells treated with TP-5801(10pM to 10mM) for 72 hours. Cell confluency was
measured using IncuCyte imaging system.
(D) Schematic diagram showing the truncated from of TNK1 as a result of paracentric inversion
in L540 cells. L540 cells were treated with the indicated doses of TP-5801 or vehicle
(DMSO) and analyzed for cell growth in an Incucyte live-cell growth chamber.
(E) Table summary of the IC50 values of TP-5801 obtained by different methods.
- 48 -

(F) TNK1-AAA driven Ba/F3-luc cells were injected into the tail veil of NOD/SCID mice. The
mice were treated once daily by oral gavage with either vehicle or TP-5801 (10mg/kg).
(G) NOD/SCID mice were subcutaneously injected with TNK1-AAA driven Ba/F3-luc cells.
Once tumor size reached 150-250mm3, mice were treated once daily by oral gavage with
either vehicle or 50mg/kg TP-5801 for seven days. Luminescent signal was imaged and
quantified using IVIS imaging. Mice were euthanized after a one-week treatment and tumors
were resected and weighed.
(H) Formalin fixed and paraffin-embedded tumor tissue from the indicated mice were
immunostained for the proliferative nuclear antigen Ki-67 and counterstained with
hematoxylin and eosin (H&E).
(I) Images show the luminescent signal from panel G and the resected tumors after one week of
treatment.

Next, we evaluated the efficacy of TP-5801 in the mouse survival model from Figure 4, in
which TNK1-AAA cells were injected intravenously. In this model, daily oral administration of
TP-5801 at 10 mg/kg significantly prolonged lifespan compared to vehicle-treated mice (Figure 26F). To assess the impact of TP-5801 on localized tumor growth, we used a subcutaneous
xenograft model. After 1 week of treatment, TP-5801 induced significantly more tumor regression
(Figures 2-6G-I ). Together, these data elucidate a lead compound, TP-5801, as an anti-TNK1
small molecule.

Figure 2-7. A model of TNK1 regulation showing the contribution of MARK-mediated 143-3 binding and the unique contribution of the TNK1 UBA to kinase activation.
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Our data suggest that 14-3-3 restrains TNK1 activity by preventing its clustering into cytosolic
membrane-associated puncta, in which TNK1 is active. Once released from 14-3-3, interactions
between TNK1 and ubiquitin are essential for full TNK1 activity. Mutations that disrupt 14-3-3
binding activate TNK1, rendering it capable of driving rapid growth factor independence and
tumor growth in vivo. Also shown is the small molecule TP-5801, which inhibits TNK1 at low
nM levels and blocks TNK1-driven tumor growth in vivo.
2.5. Discussion
Our data suggest a two-step mechanism to explain how TNK1 becomes active: First, TNK1
kinase activity is unleashed by release of 14-3-3. Second, interactions between ubiquitin and the
C-terminal TNK1 UBA allow for full activation of TNK1 (Figure 2-7). To our knowledge, this is
the first example of a kinase possessing a functional ubiquitin-binding domain and relying on
ubiquitin binding for full activation. This concept of UBA involvement in TNK1 activation raises
interesting questions about the interplay between 14-3-3 and the UBA and exactly how the UBA
contributes to TNK1 activity at a structural level.
Tyrosine kinases are often activated through oligomerization, which occurs through various
forms of induced proximity/clustering

6, 89

. For TNK1, our imaging data suggest that 14-3-3

controls clustering. This is most easily seen comparing the cellular distribution of TNK1 ∆UBA,
which interacts heavily with 14-3-3 (note 14-3-3 IP in Figure 2-1), and the 14-3-3 binding-null
TNK1 ∆UBA-AAA (Figure 2-2E). These data show that loss of 14-3-3 binding induces a marked
clustering of TNK1 into cytosolic puncta (Figure 2-2E). Our biochemical data suggest that this
clustering within a heavy membrane-associated fraction (Figure 2-2H-I). Thus, the release of 143-3 may concentrate TNK1 at membrane-associated puncta, while interactions between the UBA
and ubiquitinated species within these clusters may help to align TNK1 monomers for optimal
oligomerization. It is also possible that the UBA may home or tether TNK1 to substrates. It is
notable that TNK1 ∆UBA-AAA-driven Ba/F3 cells, although highly proliferative, failed to
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migrate outside the tail, suggesting that the UBA may home TNK1 to substrates that promote cell
migration and invasion. In support of this idea, we identified a variety of putative TNK1 substrates
involved in motility and ubiquitin-related processes (Supplemental. Figure 2-2D and
Supplemental. Figure 6).
Our studies in IL-3-dependent B cell lines show that although truncation of the UBA from
TNK1 AAA diminished its activity relative to TNK1 AAA alone, it was still more active than WT
TNK1 (Figure 2-4). This was initially puzzling based on our notion that the UBA is necessary for
TNK1 activity (Figure 2-3G). However, at least two other observations provide some additional
insight: First, we consistently found that deletion of the UBA increased the levels of TNK1 protein,
which suggests the UBA may ultimately target TNK1 for degradation, perhaps by tethering TNK1
to cargo destined for the proteasome or lysosome. Second, our imaging data, mentioned above
(Figure 2-2E), indicate that 14-3-3 plays a dominant role in controlling the clustering of TNK1 at
cytosolic puncta. Taken together, these two effects (increased stability and clustering) may simply
result in a high enough local concentration of TNK1 ∆UBA-AAA at the cytosolic puncta to
promote oligomerization and activation, even in a less-than-optimal condition (lacking the UBA).
The only other member of the human ACK kinase family, ACK1, is more studied than
TNK1. ACK1 is activated downstream of receptor tyrosine kinase signaling, promotes androgen
receptor expression, and directly drives EGFR recycling after EGF stimulation

9, 14, 15, 18, 19

.

Curiously, nearly all of what is known about ACK1 function/regulation involves domains that are
absent in TNK1. The clathrin-binding domain, the Cdc42/Rac-interacting domain and the Mig6homology domain of ACK1 are all absent in TNK1, which in turn largely accounts for the shorter
sequence of TNK1. We posit that the regulatory void left by the absence of these domains in TNK1
is essentially filled by the 14-3-3 regulatory motif. This also suggests functional divergence
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between these kinases and raises interesting evolutionary questions. Why has selective pressure
maintained the core kinase domain, SH3 domain and UBA domain of TNK1 and ACK1, but driven
divergence outside these domains? Have the ubiquitin-binding properties of the TNK1 and ACK1
UBA diverged? And in the bigger picture, how different are the biological functions of these
kinases?
Another question relates to the clinical significance of TNK1 as a therapeutic target. We
began this study with the identification of TNK1 as an essential tyrosine kinase in a subset of
hematological cancers. Previous studies on TNK1, while limited in number, have been mixed—
with some suggesting a tumor suppressive function and others a pro-survival/oncogenic function12,
29, 32-34, 36

. Based on our data, we suspect that MARK- and 14-3-3-mediated suppression of TNK1

may be a point of deregulation in cancer to ‘turn on’ TNK1. One example is the Hodgkin
lymphoma cell line L540, in which a paracentric inversion has generated a truncated TNK1 that
lacks the 14-3-3 binding site. As our model would predict (Supplemental. Figure 2-5B), this
truncated TNK1 is active 32, drives the growth of L540 cells (Figure 2-6D), and is oncogenic in
the Ba/F3 system (Supplemental. Figure 2-5A), all of which is consistent with our data. Our efforts
to determine whether this truncation is frequent in cancer have been challenging—the inversion is
too small to be effectively probed by Fluorescence in situ hybridization (FISH), so the answer will
likely be found in unfiltered data from genome sequencing. Our model also suggests that cancers
deficient in LKB1 may have higher levels of active TNK1 (via inactivation of MARKs). We
propose that these observations help guide future work to evaluate TNK1 as a therapeutic target in
specific cancer settings.
In summary, these data provide a new mechanism of regulation for an understudied tyrosine
kinase and a template to target its activity in cancer. The involvement of a UBA domain in this
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mechanism underscores the need for a better understanding of PTM-binding domains in kinase
biology. Other PTM-binding domains, including bromodomains, chromodomains, as well as other
types of ubiquitin-binding domains (e.g., zinc finger), likely play underappreciated roles in helping
kinases integrate signals from complex signaling networks40, 90. In addition, the relationship
between 14-3-3 and TNK1 sheds new light on 14-3-3-mediated regulation of kinases. Recent
mechanistic studies on 14-3-3-mediated regulation of BRAF also help expand the paradigm of 143-3-kinase relationships 63, 64. It is likely that other kinases are similarly regulated by 14-3-3, but
their discovery will require deeper LC-MS/MS probing of the 14-3-3 interactome.
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2.7. Supplementary Figures

Supplementary Figure 2-1. RNAi screening of tyrosine kinases across human hematological
cancer patient samples reveals a dependency on the non-receptor tyrosine kinase TNK1.
(A) Schematic diagram of RNAi screening of tyrosine kinases across 435 hematological cancer
samples from human patients. Samples were subjected to an RNAi screen of human tyrosine
kinases, followed by measurement of cell viability.
(B) Frequency of TNK1 as the top hit (defined as the tyrosine kinase that, when depleted, has the
largest negative impact on cell survival in a given sample) from the RNAi screening of
tyrosine kinases in AML and ALL. Hit threshold is defined as 2 standard deviations below
the mean viability.
(C) A representative viability assay from an ALL patient sample showing TNK1 as the top hit
(red bar).
(D) Kaplan Meier graphs showing correlations between TNK1 mRNA levels and overall survival
and relapse-free survival in ALL patients (COG P9906 B-ALL trial, n=207). The data are
derived from gene expression microarray data of 207 pre-B ALL patients in the Children’s
Oncology Group (COG) Clinical Trial P9906. Patient survival data were obtained from the
National Cancer Institute TARGET Data Matrix
(http://targetnci.nih.gov/dataMatrix/TARGET_DataMatrix.html).
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Supplementary Figure 2-2. Co-IP and BioID proteomics identify 14-3-3 as an interacting
partner of TNK1.
(A) FLAG-TNK1 was expressed in HEK-293T cells, immunoprecipitated on FLAG resin,
followed by elution of interacting partners and analysis by LC-MS/MS.
(B) FLAG-TNK1 was immunoprecipitated as in panel A, then subject to immunoblot with
indicated antibodies.
(C) Schematic of TNK1 BioID.
(D) TNK1-BirA was expressed in HEK-293T cells supplemented with biotin, followed by
isolation of biotinylated proteins on streptavidin resin and analysis by LC-MS/MS.
(E) Streptavidin pulldowns from panel D were immunoblotted with indicated antibodies.
(F) HA-14-3-3 (WT or K49Q) was co-expressed with FLAG-TNK1 in HEK-293T cells,
followed by immunoprecipitation of HA-14-3-3 and immunoblotting with indicated
antibodies.
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Supplementary Figure 2-3. A MARK-mediated 14-3-3 binding motif that encompasses
S502 of TNK1.
(A) WT or S/T-to-A mutants of FLAG-TNK1 were expressed in HEK-293T cells,
immunoprecipitated on FLAG resin and immunoblotted with indicated antibodies.
(B) WT or S-to-E triple mutant (S500E/S502E/S505E) of FLAG-TNK1 were expressed in HEK293T cells, immunoprecipitated on FLAG resin and immunoblotted with indicated
antibodies.
(C) Schematic representation of FRET assay monitoring interaction between 14-3-3 and TNK1
peptide (amino acid 488-511). TNK1 0P peptide has no phosphorylation. TNK1 1P peptide is
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mono-phosphorylated at S502. TNK1 3P peptide contains phosphorylations on S500, S502
and S505. Graph shows average FRET ratios with error bars representing SEM.
(D) -(H) A N-terminally biotinylated 13-mer TNK1 peptide encompassing S502 was incubated
in a streptavidin-coated FlashPlateTM and subjected to a radiometric kinase assay with 245
individual S/T protein kinases. To account for signal from kinase autophosphorylation, each
assay (+ peptide) was normalized to a control with the kinase but no peptide.

Supplementary Figure 2-4. TNK1 UBA domain binds poly-ubiquitin with a high affinity
and is essential for TNK1 activity.
(A) Recombinant GST-TNK1-UBA or GST-TAB2-UBD were incubated with the combined
indicated tetra-ubiquitin for a competitive pull-down experiment at 4oC for 2 hours. GST
tagged proteins were captured on glutathione resin and immunoblotted for GST and
ubiquitin. A 10% input of tetra-ubiquitin for each linkage type was also visualized by
Coomassie staining of SDS-PAGE gel to indicate differences in gel migration of the
linkages.
(B) Bio-layer interferometry (BLI) was performed to characterize the binding between TNK1UBA/TAB2-UBD and tetra-ubiquitin. Binding kinetics were obtained from fitting processed
data to a 1:1 binding model. Graphs show representative BLI sensorgram and fit for TNK1UBA/TAB2-UBD and tetra-ubiquitin.
(C) Mock- or TNK1-expressing Ba/F3 cells from Figure 3 panel G were immunoblotted for
global phospho-tyrosine as an indicator of TNK1 activity. Cells were also immunoblotted for
GFP (expressed from the TNK1-expressing retrovirus) as a loading control.
(D) HEK293T cells stably expressing HA-14-3-3ζwere transfected with WT FLAG-TNK1,
followed by immunoprecipitation on HA resin and immunoblotting for FLAG.
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(E) Quantitation of Figure 3 panel G in the form of transformation rate, as well as (C) and (D)
from multiple replicates, shown with signals normalized to WT TNK1. Error bars represent
SEM.

Supplementary Figure 2-5. A mutant of TNK1, generated by paracentric inversion in a
Hodgkin lymphoma cell line, drives growth factor-independent proliferation.
(A) Ba/F3 cells were transduced with either pMIG-empty vector, WT TNK1 or the D472* TNK1
(to mimic the naturally occurring mutation in L540 cells) were analyzed for IL-3 independent
growth as in figure 3G.
(B) A table showing the effect of various mutations on TNK1 kinase activity.
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Supplementary Figure 2-6. Bioinformatics evaluation of putative TNK1 substrates.
(A) Venn diagram of unique protein from each category. Included proteins are at least 2-fold
higher in signal comparative to background (MOCK) and have a p-value lower than 0.05.
(B) Phospho-tyrosine substrates that were significant and displayed a fold change of two or
greater (relative to control) in TNK1-AAA alone were subjugated to STRING DB network
analysis and visualized in Cytoscape. Node color represents magnitude of fold change. A
ubiquitin-related subset of interactors (highlighted) was selected using GO-terms and manual
curation.
(C) TNK1-WT- driven Ba/F3 cells and BCR-ABL-driven Ba/F3 cells were treated with vehicle
(DMSO) or 0.5 µM Niclosamide for 72 indicated time. Cell confluency was measured using
IncuCyte imaging system.
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Supplementary Figure 2-7. The development of a potent TNK1 inhibitor, TP-5801.
(A) Left panel shows a schematic outline of the development of TP-5801. Right panel shows the
TP-801 docking pose in the TNK1 active site homology model.
(B) Schematic diagam of TP-5801 docking pose in the TNK1 active site homology model.
(C) Diagram of TP-5801 nano-BRET IC50.
(D) IC50 graph of TNK1-WT driven Ba/F3 cells or BCR-ABL-driven Ba/F3 cells treated with
Asciminib (1pM to 10mM) for 72 hours. Cell confluency was measured using IncuCyte
imaging system.
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3. Future Directions and Summary
3.1. Role of TNK1 UBA in regulating kinase activity
Our data reveal the first regulatory mechanism of the poorly understood tyrosine kinase
TNK1 by 14-3-3 binding and ubiquitin-binding property of its UBA domain. While it seems clear
that 14-3-3 binding on TNK1 controls its localization/clustering, the role the UBA plays in kinase
activation requires further investigation. To our knowledge, TNK1 is the first example of a kinase
possessing a functional ubiquitin-binding UBA domain, which TNK1 relies on for full kinase
activation. This concept raises interesting questions for future studies.
First, is ubiquitin binding alone sufficient to activate TNK1? From our data, mutations that
interrupt ubiquitin binding reduced TNK1 kinase activity. This observation suggests that ubiquitin
binding is an essential part of the TNK1 mechanism of activation. Second, since UBA domains
are often found in proteins involved in degradation pathways, could TNK1 play a role in
proteasomal degradation or autophagy? p62/SQSTM1 is an autophagy receptor, which also has a
functional UBA domain at its C-terminus91, 92. With the UBA domain, p62 binds and loads
ubiquitinated cargo to the autophagosome for degradation. From our BioID data, we found that
TNK1 interacts with multiple autophagy-related proteins, including p62/SQSTM1, ATG2A/B and
TBK1. Our confocal data confirms that TNK1 co-localizes with p62/SQSTM1 (figure 3-1). We
also found that TNK1 interacts with all three forms of the autophagy marker light chain 3 (LC3)
(data not shown). However, the question of whether TNK1 plays a role in autophagy or simply is
degraded via autophagy still requires further investigation. Third, is the UBA domain of ACK1,
the only other human kinase in the ACK family, also functional and does it play a role in kinase
regulation? There is no still study validating whether the ACK1 UBA can bind to ubiquitin.
However, a mutation within the UBA domain of ACK1 led to increased cancer cell proliferation
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and migration45. The mechanism of how the mutation affects ACK1 kinase activity and its UBA
will be an important future direction.

Figure 3-1 TNK1 UBA domain is required for co-localization with p62/SQSTM1.
(A) HEK-293A cells expressing FLAG-TNK1 (WT or ∆UBA) were analyzed by confocal
imaging for FLAG-TNK1 and p62/SQSTM1 localization.
(B) FLAG-TNK1 and p62/SQSTM1 co-localization was analyzed using Leica 3D analysis.
Within the TNK1 UBA domain, there is a prominent tyrosine phosphorylation. Indeed, it
is the most frequently identified tyrosine phosphorylation across the entire sequence of TNK1. We
found that a phospho-defective mutation at this site (Y661F) slightly reduced 14-3-3 binding on
TNK1, while a phospho-mimicking mutation (Y661E) increased 14-3-3 binding on TNK1 (figure
3-2). Given the importance of the UBA in TNK1 activity, I posit that phosphorylation of Y661
could be an important regulatory mechanism for TNK1. However, we still do not know the precise
function of Y661 phosphorylation (most importantly, its effect on ubiquitin binding), nor the
kinase that mediates this phosphorylation (these studies are currently underway)
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Figure 3-2 Phospho-mimicking mutation at Y661 increases phosphorylation at S502 and
14-3-3 binding. WT and mutant FLAG-TNK1 were immunoprecipitated from HEK-293T cells
and immunoblotted for 14-3-3 binding (upper) and TNK1 phosphorylation at S502 (lower).
Graphs show quantitation of infrared signal from multiple replicates with signals normalized to
WT. Error bars represent SEM.
3.2. Oligomerization
NRTK activity often requires dimerization/oligomerization. ACK1 requires its N-terminal
SAM domain for dimerization and activation. The ACK1 SAM domain is also required for
membrane association4. (Interestingly, mutations within the SAM domain, R34L and R99Q,
activate ACK1 by an unknown mechanism.11) Like ACK1, TNK1 also possesses an N-terminal
SAM domain. We have posited that interactions between the TNK1 UBA and ubiquitin may
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facilitate TNK1 oligomerization by a mechanism of “induced proximity”. However, the
requirement for oligomerization in TNK1 activation and the role of the UBA in the process, is
currently known.
3.3. Migration
We have shown, via Bio-ID proteomics, that TNK1 interacts with multiple migration-related
proteins (sup. figure 2-2). These data made us question whether TNK1 may be involved in
promoting cell motility. To test this idea, we demonstrated that TNK1 KO cells show limited
movement comparing to the WT cell and it is demonstrated in different cell lines (figure 3-3).
These data suggest that TNK1 promotes cancer cell motility.

Figure 3-3 TNK1 KO restrains cells migration. SKBR3 and MCF7 CRISPR/Cas9 TNK1 KO
and parental cell lines were analyzed for motility in a CellASCICS chamber. Cells were tracked
every 10 minutes for 12 hours. The path of each cell and distance traveled is shown by each line
in graphs on left.
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3.4. Summary
In conclusion, our data uncover the first mechanism of TNK1 regulation, including the first
example of a functional UBA domain on a kinase. We have also discovered a lead compound for
development of a TNK1-targeted therapeutic. However, there is still much work to be done to
understand the general function of TNK1 in human biology and additional details regarding
TNK1 regulation. The unpublished preliminary data shown in this chapter demonstrate a few of
the important future directions for this project, including 1) the interacting partners of TNK1; 2)
additional regulatory modifications on TNK1; 3) the normal function/role of TNK1 in cells. In
addition, it will be important to thoroughly characterize the role of ubiquitin binding in TNK1
activation and function.
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